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ABSTRACT
One out of every three people will suffer either a stroke or develop Alzheimer’s disease (AD).
In  a  world  with  continuous  increase  of  life-expectancy  the  burden  to  healthcare  system
caused by these two neurological disorders will increase dramatically. It has become
apparent that these two diseases share common pathological features, and this knowledge
can be used to our advantage in finding new treatments.
Focal cerebral ischemia in rodents is followed by delayed secondary pathology in the
thalamus and this  involves  amyloid- (A)  and calcium aggregation.  This  thesis  has  been
done to further advance our understanding of the mechanisms behind this secondary
pathology after cerebral ischemia and whether this pathology could be modified by the non-
steroidal anti-inflammatory drug ibuprofen (study I), the non-selective calcium channel
inhibitor, bepridil (II and IV) and the reverse Na+/Ca2+ exchanger inhibitor, KB-R7943 (III).
In study II, bepridil treatment after middle cerebral artery occlusion decreased the
amounts of A40 and A42 as well as calcium levels in the ipsilateral thalamus in rats.  The
sensorimotor impairment was improved in bepridil treated MCAO animals. The data
indicate that bepridil treatment prevents or modifies secondary pathology in the thalamus
improving functional outcome.
In  study  IV,  transgenic  AD  mice  were  treated  with  bepridil  after  photothrombotic
cortical lesion. There appeared to be less pronounced primary and secondary pathology in
AD mice after ischemic cortical injury. It  may be that the underlying AD pathology in the
transgenic animals exerted a protective effect against cortical ischemic damage. The calcium
pathology in the thalamus was effectively prevented by bepridil treatment.
In study V, common marmosets subjected to transient middle cerebral artery occlusion
were followed for forty-five days. The histological evaluation conducted after the follow-up
did not show A or calcium aggregates in the thalamus similar to those found in rodents.
The data from studies I and III suggest that chronic ibuprofen or KB-R7943 treatment
in rats does not improve behavioral outcome nor prevent secondary pathology in the
thalamus after experimental focal ischemia.
Secondary pathology after stroke is an attractive drug target since it  has an extended
therapeutic time window. Bepridil seems to alleviate the secondary pathology via a non-
inflammatory pathway and without interfering with amyloid precursor protein or A
cleavage and clearance. Data from these rodent studies indicates that calcium plays a more
pivotal role than A in the secondary pathological changes in the thalamus. The results from
non-human primates after cerebral ischemia, however, show a complete lack of secondary
pathology indicating that this may be a rodent specific phenomenon, which is likely to
complicate translation of the data from rodents to humans.
National Library of Medicine Classification: WL 356, QV 276, WD 205.5.A6, QZ 150
Medical Subject Headings: Stroke/pathology; Brain Ischemia; Infarction, Middle Cerebral Artery; Thalamus;
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Sodium-Calcium Exchanger/antagonists & inhibitors; Behavior; Disease Models, Animal
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TIIVISTELMÄ
Joka kolmas meistä sairastuu elämänsä aikana aivoverenkiertohäiriöön tai Alzheimerin
tautiin (AT). Keskimääräisen elinajanodotteen kasvaessa myös näiden sairauksien
aiheuttama sosioekonominen taakka yksilölle ja yhteiskunnalle kasvaa merkittävästi. Näillä
sairauksilla on monia yhteisiä piirteitä, mikä tarjoaa lähtökohtia uusien hoitojen
kehittämiselle. Sekä Alzheimerin taudissa että aivoiskemiassa on havaittu esimerkiksi
kalsiumin ja amyloidin-beeta:n (A) kertymistä. Aivoiskemian jälkeen nämä muutokset
ilmaantuvat viiveellä varsinaisen infarktialueen ulkopuolelle kuten talamukseen.
Tässä väitöskirjatyössä selvitettiin kortikaalisen aivoiskemian jälkeen tapahtuvia
sekundaarisia muutoksia ja eri lääkeaineiden tehoa niiden estämisessä. Lääkkeinä käytettiin
tulehduskipulääke ibuprofeenia, ei-selektiivistä kalsiumkanavan salpaajaa bepridiiliä tai
käänteisen natrium-kalsium-ioninvaihtajan estäjää KB-R7943:a.
Osatyössä II kokeellisen aivoiskemian jälkeen rotille aloitettu bepridiili-lääkitys laski
A40:n  ja  A42:n sekä kalsiumin määrää talamuksessa. Myös sensorimotoriset
käyttäytymistestit osoittivat lääkinnän nopeuttavan rottien toipumista. Tulosten perusteella
voidaan olettaa, että bepridiili-hoito joko estää tai hillitsee haitallisia muutoksia
talamuksessa ja näin ollen nopeuttaa toiminnallista kuntoutumista.
Osatyössä IV AT-muuntogeenisille hiirille aloitettiin bepridiili-lääkitys
valosensitiivisellä aineella aiheutetun kortikaalisen aivoiskemian jälkeen. Tulosten
perusteella aivoiskemian aiheuttama kalsiumin ja A:n kertyminen oli AT-hiirillä
vähäisempiä kuin villityypin hiirillä. On mahdollista, että Alzheimerin taudille tyypilliset
muutokset suojelevat AT-hiiriä aivoiskemian vaikutuksilta. Myös tässä tutkimuksessa
bepridiili-lääkitys vähensi myös tässä tutkimusessa kalsiumin ja A:n kertymistä
talamukseen.
Osatöiden I ja III tulosten perusteella pitkäaikainen ibuprofeeni- tai KB-R7943- hoito
aivoiskemian jälkeen ei estä muutoksia rottien talamuksessa.
Viidennessä osatyössä kortikaalinen aivoiskemia aiheutettiin apinoille. 45 vuorokautta
myöhemmin tehty histologinen tutkimus ei osoittanut aivojen talamuksessa sellaisia A- tai
kalsiumkertymiä kuin jyrsijöillä on havaittu.
Aivoiskemian jälkeen tapahtuvat sekundaariset muutokset ovat kiinnostava kohde
uusille lääkehoidoille, koska ne ilmaantuvat viiveellä ja hoidon aloittamiseen jää enemmän
aikaa. Bepridiili näyttäisi vähentävän näitä haitallisia muutoksia. Se ei vaikuta
tulehdusprosessiin eikä A:n tai sen esiasteen käsittelyyn. Jyrsijöillä tehtyjen kokeiden
perusteella kalsiumilla näyttäisi olevan A:a tärkeämpi rooli talamuksen haitallisissa
muutoksissa. Kuitenkin apinoilla tehty työ osoitti, etteivät aivoiskemian jälkeiset muutokset
ole kädellisillä samanlaisia kuin jyrsijöillä. Näin ollen kokeelliset tutkimustulokset eivät
välttämättä ole suoraan sovellettavissa ihmisiin.
Luokitus: WL 356, QV 276, WD 205.5.A6, QZ 150
Yleinen Suomalainen asiasanasto: aivohalvaus; aivoinfarkti; iskemia; talamus; kalsium; amyloidi; tulehdus;
kalsiuminestäjät; ibuprofeeni; bepridiili; koe-eläinmallit
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1 Introduction
In global terms, in a single year, there are over 16 million strokes and almost 6 million people
die because of a stroke 1. In addition, stroke is one of the leading causes of disability. By the
year 2030, it has been estimated that 10.3 % of all deaths will be caused by a stroke and the
incidence rate will have increased by a three million further. Certainly, stroke is one of the
most costly global wide non-communicable diseases. One can also estimate, that the cost of
stroke today in the developed world (266 billion to 1038 billion USA dollars) will double by
the year 2030 due to the aging of the population 2.
Alzheimer’s disease (AD) is the most common type of dementia; it is characterized by
neuronal loss and the typical amyloid- (A) pathology. The death or malfunction of neurons
causes changes in memory, behavior, and the ability to think clearly. These neuronal changes
eventually impair an individual's ability to carry out even basic functions such as walking
and swallowing 3. It is estimated that currently around from 24 to 36 million people around
the world have dementia,  in most cases AD, and this number is going to double every 20
years. Sixty percent of dementia patients live in developing countries; this proportion will
increase to more than 70 % by 2040. The current evidence suggests that vascular factors, such
as midlife hypertension and cerebrovascular disease, contribute significantly to the
development of dementia and Alzheimer's disease 4,5. Worldwide, the annual economic cost
of dementia has been estimated as 315 to 604 billion USA dollars 6,7.
One out of six people will suffer a stroke during their lifetime. One in three individuals
will suffer either stroke or dementia 8.  Therefore,  it  seems  that  not  only  can  the  two
pathologies occur together, but they also may interact.  Several studies have shown that AD
and ischemic brain injury leads to altered amyloid precursor protein (APP) processing 9,10,
A accumulation 11–14, and increased neuroinflammation 15.  In  both  diseases,  impaired
calcium homeostasis has been demonstrated in multiple studies 16. Neurological deficits
following acute cerebral infarction are associated with not only primary injury but also with
the secondary damage in remote loci linked to the infarction site 17–21.
In view of the numbers of deaths, disability and cost attributable to these neurological
disorders, and the fact that these disease entities may interact, a treatment focused on the
common neuropathology would be extremely beneficial. This thesis focuses on
understanding the secondary pathology after experimental stroke involving pathology
typical to AD.
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2.1 ISCHEMIC STROKE
Blood clotting is essential for survival in everyday life. Wounds will be closed because of the
clotting processes activated in the blood and vessels. However, in the case of stroke, blood
clots are dangerous because they block the blood flow and interrupt the supply of oxygen
and nutrients in the brain. This event is called ischemia and it can occur in two ways.
In an embolic stroke, a blood clot is formed somewhere in the body, most often in the
heart.  This  clot  travels  via  the  peripheral  vascular  system  into  the  brain  and  eventually
reaches a vessel so small that the clot cannot pass through and this will block the blood flow.
This peripherally formed clot is called an embolus, which gives the name to this subgroup of
strokes 22.
In  a  second  subgroup  of  strokes,  the  clot  called  a  thrombus  develops  in  the  arteries
supplying the blood to the brain. In most cases, this plaque is a rupture from a “large artery
atherosclerosis”, a situation usually traceable to unhealthy living habits and increase in
uptake  of  fatty  deposits  and  cholesterol,  which  accumulate  in  the  walls  of  the  vessels 23.
Usually these thrombotic strokes lead to a large vessel thrombosis, which means that the
combination of long-term atherosclerosis and the rapid formation and/or rupture of a clot(s)
eventually prohibits the blood flow in the large brain arteries. Thrombotic stroke patients are
also likely to have coronary artery disease, and ischemic heart attack is a common cause of
death in patients who have suffered this type of brain attack. In addition, myocardial
infarction has been shown to share causality to plaque rupture 24. Lacunar infarction occurs
when the blood flow is blocked in a smaller arterial vessel and usually the symptoms from
these small strokes are milder and/or unnoticeable. The “small vessel disease” is commonly
linked with hypertension 22.
Life  style  modifications  are  the  primary preventive  actions  an individual  can take to
decrease  his/her  risk  of  stroke.  The  major  risk  factors  of  stroke  have  been  characterized;
hypertension, smoking, diabetes, atrial fibrillation and certain other cardiac related
conditions, dyslipidemia, carotid artery stenosis, sickle cell disease, unhealthy diet, physical
inactivity and obesity. Other risk factors are metabolic syndrome, excessive alcohol
consumption, drug abuse, use of oral contraceptives, sleep-disordered breathing, migraine,
hyperhomocysteinemia, elevated lipoprotein levels, hypercoagulability, inflammation and
infections (see 25,26).
Thrombolysis (tissue plasminogen activator; tPA) is at the present the only United
States Food and Drug Administration (US FDA) and European Medicines Agency (EMEA)
approved drug treatment for acute ischemic stroke 27–29. It is unfortunate that tPA-treatment
is possible for only patients who are in the hospital or in a special mobile stroke unit 30. Since
tPA-infusion should be started at the latest within 3 - 4.5 hours from the onset of initial signs
of  an  ischemic  event.  After  this  time  window  the  possible  risks  outweighs  the  possible
benefits. It seems that patients under 75 years old having mild to moderate stroke symptoms
are more likely to benefit from tPA treatment (see 31,32). Nonetheless, the limitations
associated with tPA-treatment leaves almost 90 - 95 % of acute stroke patients without any
effective drug intervention 33–35. In Finland, and particularily in Helsinki, the situation is much
better, and almost 30 % of hospitalized stroke patients receive tPA treatment 36.
4There are from 33 up to 55 million survivors living with the consequences of a stroke
1,37. Based on statistics from the USA, at 6 months after stroke onset, 50 % of stroke survivors
were experiencing some hemiparesis, 30 % were unable to walk without some assistance,
and 26 % were dependent in activities of daily living, 19 % had aphasia, 35 % had suffered
depressive symptoms and 26 % required institutional care 37.
Despite decades of scientific work into the pathology behind the disease, setbacks
continually plague the search for an effective cure and treatment for the disease 38. Therefore,
there is a great need to develop new therapeutic approaches which can be used in patients
with cerebrovascular diseases.
The events that take place after the initial stroke are schematically presented in Figure
1. After the primary blockade of the artery, many distinct processes become activated in the
ischemic core and perilesional areas. Cell death and edema with energy failure develop
quickly  and  thus  these  represent  one  possible,  but  challenging,  target  for  acute
neuroprotection. After the primary devastating cell death, the brains own repair pathways
are activated, and these can be promoted with different activators to lead into new neuronal
connections to compensate for the lost ones. Weeks after the initial stroke, cell therapy and
cortical stimulations may represent novel ways to aid the brain’s own plasticity and recovery
39. It should be noted that in particular inflammatory processes remain active for months after
the ischemic event which means that these secondary pathological changes may have impact
on the patient’s life long after the acute stroke.
Figure 1: Timeline of events after ischemia. The intensity of color represents the level of activity
in changes in the brain and the optimal time to influence these events with different therapies.
The inflammation cascade begins shortly after the ischemic event and stays active for months.
Secondary  pathologies  take  place  one  week  after  the  onset  of  stroke  and  also  continue for
months. Modified from Wieloch and Nikolich 39.
52.2 ALZHEIMER’S DISEASE
Dementia competes with stroke for first place as the leading cause of functional disability in
the elderly 40,41. In 2010, the global prevalence of dementia was estimated to be almost 36
million individuals, with an annual societal cost of 604 billion dollars 7. In addition, another
estimate is that over 115 million people will have lived with dementia before the year 2050 5.
It is well known that AD represents the majority (60-70 %) of all dementia cases 6. Although
it is difficult to assess the cause of death in AD patients, the general estimation is that the
majority (61 %) of individuals with AD at age 70 will die before the age of 80, as compared
with only 30 % of correspondingly aged people not suffering from AD 42.
The key protein aggregates that are considered as hallmarks for AD are the extracellular
A-plagues which are mainly comprised of A40 and A42 monomers derived from APP, and
intraneuronal neurofibrillary tangles (NFTs) containing microtubular hyperphosphorylated
tau (see 43). It is noteworthy that there is a vigourous debate about whether these two
hallmarks  should  be  considered  as  “damage  response  proteins”  rather  than  being  actual
causes of the disease 44.
Furthermore, epidemiological studies have shown that the risk factors for stroke are
associated  with  AD  and  that  malign  cerebrovascular  changes  can  be  detected  in  a  high
proportion of autopsy samples of AD patients 45,46. In addition, stroke intensifies the presence
and worsens the severity of the clinical symptoms of AD as well as increasing AD-specific
pathology in the brain 47,48.
However, AD is not simply a secondary disease caused by a brain injury. In addition,
genetic factors can be a major contributor to early-onset AD. In these relatively rare early-
onset ADs, the neurological symptoms are diagnosed before the age of 65 (34% from all
dementias under the age 65) 49. In both the early-onset and late-onset forms of AD, the 4-kDa
A peptide  cleavage  products  from  -  and  -  secretases  have  been  considered  as  causal
factors in AD 50–52. In early-onset AD, there is an increase in A cleavage due to an inherited
mutation in APP or presenilin (PSEN) 53. In late-onset AD, the elevated enzymatic cleavage
occurs in some patients who have a high level of -secretase (BACE) 54. In addition, a decrease
in the A degrading enzymes may lead to late-onset AD 55.
At the moment, there is no treatment for reversing the progress of AD. During the last
decade, over 100 compounds for the treatment of AD have been tested in clinical trials but
all have failed 56. The treatments for AD at the moment are merely palliative for the symptoms
rather than curing the disease itself. The main target for these compounds are based on two
hypothesis; first that in AD there is a cholinergic deficit (e.g., treatment with a cholinesterase
inhibitor) or second, there is an excessive NMDA receptor tone (e.g., treatment with an
NMDA receptor antagonist such as memantine). Both of these treatment approaches have
achieved at best only mild to moderate treatment effects in patients 57.
Similar to stroke, the only way to reduce the risk of developing AD can be found in life-
style modifications. By preventing any additional brain injury such as stroke or traumatic
brain injury, the risk of premature development of AD can be also decreased.
2.3 PRIMARY NEUROPATHOLOGY AFTER STROKE
Acute ischemic damage is a consequence of a cascade starting from energy depletion in the
brain. Thus the fast restitution of blood flow into the ischemic areas is crucial in preventing
further energy and sodium/potassium (Na+/K+)  pump  failure,  increase  in  ionic  influx,
increase in intracellular calcium (Ca2+), depolarization, cell swelling, generation of free
radicals, blood-brain barrier (BBB) damage, inflammation and apoptosis (see Figure 2 and 58–
60).
6The ischemic event is described as a situation when cerebral blood flow (CBF) is
reduced to 75-80 % below normal level or is less than 10 ml/100g/min 58,61. Since nutrients,
like the levels of glucose and oxygen are too low in target brain areas, adenosine triphosphate
(ATP) production and cellular metabolism in the brain becomes dysfunctional. This rapidly
leads to an efflux of K+ ions, which in turn causes an influx of Na+ and Ca2+ into the cells (see
62) and release of excitatory neurotransmitters such as glutamate (see 63). The accumulation of
the calcium in the cells leads to a rapid and extensive breakdown of phospholipids, proteins
and nucleic acids by activation of calcium-dependent phospholipases, proteases and
endonucleases 58. Due to the K+ synergized neurotransmitter release, N-methyl-D-aspartate
receptor (NMDAR) and -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors
(AMPAR)  are  activated,  thus  elevating  the  intracellular  Ca2+ concentration. In addition, a
high intracellular Ca2+ concentration activates cytosolic proteases, which can directly affect
the intracellular microtubule-trafficking and proteolytic degradation of structural and
functional proteins (see 58).
Subsequently, free fatty acids are transformed via lipid peroxidase into toxic
substances, which in turn endanger cellular functions. Free radicals inflict damage to lipids,
deoxyribonucleic acid (DNA) and proteins, thus accelerating neuronal death. Highly reactive
oxygen  species  also  contribute  to  the  BBB  breakdown  and  brain  edema.  Plasminogen
activators and matrix metalloproteinase (MMP) are the two major protease systems that
modulate  the  matrix  in  the  brain  thus  having a  critical  impact  on functioning of  the  BBB.
Inhibition of MMPs after ischemia has been shown to reduce infarct size, the extend of brain
edema and hemorrhage 64. The disruption of the matrix leads to dysfunctional neurovascular
signaling between cells 65. In conjunction with endothelial hypoxic damage, inflammatory
molecules  and free  radicals,  MMPs further  aggravate  the  damage done to  the  BBB by the
stroke 58,66. Other studies have shown that MMPs are intimately involved in angiogenesis via
vascular endothelial growth factor 67.
Within minutes of blood deprivation in the brain, the endothelial cells start to express
adhesion  molecules  such  as  intracellular  adhesion  molecule-1  (ICAM-1)  or  vascular  cell
adhesion molecule-1 that help leukocytes adhere to the endothelium in the arterial wall, thus
enabling  these  molecules  to  migrate  into  the  brain  parenchyma 68–70. At the same time,
activated leukocytes (e.g., granulocytes, monocytes/macrophages, lymphocytes) produce
proinflammatory cytokines, like tumor necrosis factor alpha (TNF-) as well as interleukins,
and chemokines 58,65,71. Microglial cells participate not only in producing proinflammatory
cytokines, but also in the production of free oxygen radicals and the enzyme cathepsin during
the initial inflammatory response.
In addition, nitric oxide (NO) has an important role in multiple physiological processes
like  neuronal  communication,  host  defense  and  regulation  of  vascular  tone  (see 71).
Inflammation causes excessive NO release in the brain and is also one of the culprit factors
in axonal degeneration 72. Pharmacological studies have shown that inhibition of the
inducible calcium independent isoform of NO synthesis can reduce the infarct size by about
30 % after cerebral ischemia 73.
DNA can be damaged if it becomes exposed to severe oxidative stress such as occurs in
a stroke. The DNA damage can be divided in two distinct types; active and passive DNA
damage (see 74).  In  active  DNA  damage  the  endonucleases  orchestrate  apoptotic  DNA
fragmentation, in which the two main endonucleases are caspase-activated deoxynuclease
and apoptosis-inducing factor. In passive DNA damage, the main players are reactive
oxygen radicals (ROSs). During the postischemic DNA accumulation, the DNA synthesis
process is dysfunctional and gene transcription is disrupted thus activating apoptotic cell
death 75. Apoptotic cell death, mainly observed in the penumbra, begins immediately after
the onset of the stroke and it remains highly active for days 76,77.
72.4 SECONDARY NEUROPATHOLOGY AFTER STROKE
After cerebral infarction, neuronal death, gliosis, and axonal degeneration have been found
in the ipsilateral thalamus, substantia nigra and distal pyramidal tract, all of which are
located outside the regions supplied by blood from the middle cerebral artery (MCA) 17,78–82.
In addition to axotomy and neuronal loss, secondary pathology in the remote areas seems to
be far more complex, including A and calcium deposition.
2.4.1 Degeneration of corticothalamic and thalamocortical connections
It is well established that in mammals the ascending information reaching the cerebral cortex
derives primarily from thalamic relay nuclei. The prominent thalamocortical projection is
associated with an even denser reciprocal corticothalamic projections, allowing the cerebral
cortex  to  exert  what  is  generally  considered  as  a  descending  feed-back  control  on  the
thalamus 83.
In  general,  the  thalamus  can  be  divided  into  two  regions  based  on  the  origin  of  the
input. The so called “first-order” thalamic nuclei receive connections from subcortical centers
(e.g.,, retina, spinal cord and cerebellum) and thus transmit visual, somatosensory and motor
information. “Higher order” thalamic nuclei, such as the lateral dorsal nucleus (LD) and the
lateral  posterior  nucleus  (LP),  receive  inputs  from  cortical  layer  5  pyramidal  cells  and
participate in cortico-cortical information transfer via the thalamus (see 83–85). Rodent studies
have revealed that corticothalamic connections from the primary somatosensory cortex
terminate in the reticular nucleus of the thalamus (RTN), ventroposterior medial nucleus
Figure 2: Schematic picture of ischemic cascade in cellular level. Ischemic cascade starts from
the  blockage  of  blood  flow  (CBF)  which  inhibits  oxygen  and  nutrition  transport  to  the  brain
eventually leading to intracellular calcium overload. AMPAR: -amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid, NMDAR: N-methyl-D-aspartate receptor, KA: kainate receptor, NO:
nitric oxide. Endothelial inflammation activates cytokine release and inflammatory blood cells,
which in turn promotes intracellular free radicals and thus accelerates cell death.
8(VPM) and ventroposterior lateral nucleus (VPL), as well as the nuclei of the posterior
complex 86. A recent study revealed that the ventral lateral thalamic nuclear complex (VLa–
VLp) is more connected to the motor cortical areas, also receiving cerebellar and basal ganglia
afferents and sending projections to the motor-associated cortical areas 87. Corticothalamic
relays are mostly connected via gamma-aminobutyric acid (GABA)ergic connections
between globus pallidus (GP), RTN and ventroposterior nucleus complex (VPN), which in
turn projects with glutamatergic signals to cortical layers (Figure 3,  mouse sagittal images
from 88).
Since it known that thalamus has an important role as a signal controller between
cortical  and  subcortical  areas,  one  may  ask  what  would  happen  were  the  thalamus  to  be
damaged? In experimental middle cerebral artery occlusion (MCAO) studies, the thalamus
is spared from acute ischemic damage, but because of its synaptic connections to the cortex,
it can suffer delayed retrograde degeneration of thalamocortical neurons. In addition, the
Wallerian (anterograde) degeneration of corticothalamic connections takes place soon after
the cortical injury. At the ultrastructural level, retrograde degeneration involves
degeneration of corticothalamic terminals, swelling of thalamic astrocytes and dissolution of
endoplasmic  reticulum  (ER)  within  perikarya  of  affected  neurons.  As  the  degenerative
process continues, thalamic neurons die 89.
 APP  is  one  of  the  markers  for  axonal  injury;  this  form  accumulates  because  of  the
disruption of fast anterograde axonal transport after various brain insults 90. After MCAO,
APP immunoreactivity is acutely localized within axonal swellings, dystrophic neurites, and
neuronal perikarya all along the periphery of the infarct 91. Later, there is an increase in APP
staining in the corpus callosum in crossing axons, in descending axons leaving the lesioned
area, and in the terminal zone of these axons in the thalamus 92.
Understandably, impaired axonal transport has been described also in AD. Recent
studies have shown axonal deficits in AD through swellings that have accumulated abnormal
amounts of microtubule-associated and molecular motor proteins, organelles and vesicles 93.
It has been postulated, that this is largely mediated by the kinesin-I-related fast anterograde
transportation pathway within the axon 94,95. The same mechanism also seems to be relevant
in the accumulation process of A42 and increase of the A42/A40 ratio in the axons 93. Poon
et al 96 also showed that soluble A assemblies cause synaptic dysfunction by disrupting both
neurotransmitter and neurotrophin signaling, thus again blocking the axonal trafficking.
Figure 3: Schematic figure shows corticothalamic and thalamocortical connections (modified
from  Dihné  et  al.  2002 108 and Paxinos 2001 88). After MCAO, thalamocortical connections
undergo retrograde degeneration. In addition, damage to globus pallidus (GP) decreases
inhibitory control on the reticular thalamic nucleus (RTN) leading to overexcitation of
ventroposterior thalamic nucleus (VPN) and excitotoxic cell damage.
9Furthermore, evidence from mouse models of AD have revealed a correlation between
white matter diminish and APP deficiency 97,  and  this  was  also  detected  in  the  magnetic
resonance imaging (MRI)  imaging studies 98.  Interestingly, it has been shown that axonal
swelling occurs long before detectable A deposits can be observed in the AD mouse 93,99 and
in humans 100. Several studies have demonstrated that the presence of A can accelerate the
accumulation of microtubule-associated tau-protein, which deposits in AD brain as
hyperphosphorylated aggregates or neurofibrillary tangles 101–106. Similar changes have also
been seen after a traumatic brain injury in transgenic AD mice; in these animals the intra-
axonal A accumulation and increased phosphorylated tau immunoreactivity was detectable
for  seven  days.  Treatment  with  a  -secretase  inhibitor  was  able  to  prevent  the  axonal  A
accumulation without effecting the tau pathologies 107,  suggesting  that  A and  tau  are
independently  affected  by  trauma.  More  recent  studies  have  shown  that  also
hyperphosphorylated tau tends to aggregate in the ipsilateral thalamus after MCAO 108.
2.4.2 Neuronal loss and shrinkage of thalamus
Acute  ischemic  cell  death  is  mediated  mainly  by  necrotic  and  apoptotic  pathways.  The
primary ischemic insult can be considered mainly as a necrotic event, in which a cell and its
organelles swell and lose membrane integrity and ultimately release inflammation inducing
factors which can damage the neighboring cells 109.
In addition, MCAO results in delayed neuronal loss in both the VPN and RTN. Glial
activation occurs  in  both nuclei  beginning after  24  hours 110. The RTN, like other thalamic
nuclei, is supplied by the posterior cerebral artery 111. Thus, occlusion of the MCA alone does
not induce any significant reduction in regional cerebral blood flow within the thalamus 112,113.
Vasogenic fluid spreading from the area suffering the infarction may be a contributor to the
neuronal  damage  in  the  VPN  after  transient  MCAO 114,115 but not after photothrombotic
cortical lesion 116 possibly  because  of  a  smaller  size  of  edema  or  because  of  the  intact
GABAergic projection from the GP into the RTN 110.
Due to anterograde and retrograde axonal degeneration and neuronal damage, severe
atrophy takes place in the thalamus 117. Within weeks, the the atrophy can be seen in imaging
studies from stroke patients 80 as well as in rodents 117.
2.4.3 Inflammation
The majority of stroke patients have a co-morbid systemic inflammatory disease like
diabetes, atherosclerosis, obesity, hypertension or peripheral infection 118,119,  which  are  all
known to be risk factors for stroke. A chronic increase in the numbers of inflammatory cells
in the blood circulation has been proposed to be one of the causal factors also in AD, since
the factors released by these cells can increase the permeability of the BBB 120. In addition,
dysfunctional A clearance through BBB via RAGE-mediated pathway may be affected by
inflammation and thus accelerate the onset of the disease 121.
In acute stroke, there seems to be BBB leakage into the ischemic core, thus enabling
blood  derived  cells  to  gain  access  into  the  brain,  which  in  normal  situations  has  a  very
different immune system compared to that present in peripheral tissues (see 122). In addition,
upregulation of TNF expression after stroke by neurons and astrocytes has been shown to
increase the BBB permeability 123.  The brain  has  a  tendency to  quickly  restore  the  cerebral
blood flow after stroke, thus BBB permeability is at its highest during this restoring process
124.
In the brain, the immediate response to injury is the activation of astrocytes, which in
turn facilitates microglia activation (see 125). Astrocytes maintain the homeostasis in the brain,
thus when they are dysfunctional, this may lead to multiple other neurological diseases.
There are studies of experimental models of stroke revealing a connection between inhibition
of astrocytic activation and improved functional recovery 126. In addition, microglia cells have
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multiple ways to facilitate rapid sequestration and destruction of invading microorganisms
as they strive to limit the effect of trauma and cell necrosis (see 127). The activation of microglia
cells has a contribution to neurodegenerative diseases, but the question “how” is still a matter
of debate. Migration and phagocytosis are promoted via activated microglia cells; there is
also  the  release  of  many  inflammatory  mediators  e.g.,  superoxide  anions  and  nitric  oxide
(NO).  Recent  studies  have  shown  that  microglia  could  be  an  additional  source  of
inflammatory cytokines, which makes these cells an interesting target for acute stroke
treatment (see 128). Since the activation of microglia is a slow process (hours to days), it offers
a wider time window for drug intervention 129.
Thus, if one inhibits the inflammatory response, then the infarct size may be decreased
and neurological deficits improved in experimental stroke 130. There is a report that TNF-
was upregulated in the ipsilateral thalamus one day after experimental MCA occlusion, and
the microglia/astrocyte reaction which became activated after three days persisted for up to
6 months 131,132. In contrast, neuronal degeneration was initiated only four days after MCAO,
and it became evident after 14 days 131,133.
In addition, prevention of peripheral infections with antibiotic treatments has been
shown to improve the outcome after stroke 134–136. The rationale for this might be that by
preventing the excess activation of immune cells in the peripheral tissues, also the amount of
peripheral immune cells penetrating through the BBB would be reduced and thus this would
lessen the burden within the ischemic area.
2.4.4 Autophagy
Autophagy is a major intracellular degeneration cascade which acts in contact with
lysosomal elimination and recycling of damaged organelles and aged proteins (see 137).
Effective clearance of autophagosomal structures needs retrograde transportation into the
soma, where the majority of lysosomes are situated. Beclin 1 and LC3-II are two of the best
known autophagosomal protein markers 138 which have been shown to be upregulated after
focal ischemia 139.  Gabryel  et  al 140 hypothesized that by keeping autophagy as an active
process and removing damaged organelles, then secondary damage could be prevented. In
contrast Ginet et al 141 claimed that autophagy exhibited regional specificity and this exerted
an impact on the worsening of the secondary damage after hypoxia in young rats 142.
Inhibition of Beclin 1 has been shown to prevent autophagy orchestrated secondary
damage in the ipsilateral thalamus after MCAO 143, which is in line with the findings that
autophagosomes can accumulate within thalamic cells after a cerebral cortical infarction. This
in turn is associated with thalamic A deposition and secondary neuronal degeneration via
elevation of -site APP-cleaving enzymes 144.
In  AD  autophagy  has  been  more  intensively  studied.  It  seems  that  the  retrograde
trafficking system and lysosomal activity is dysfunctional in AD, thus causing a massive
accumulation of autophagic elements along degenerating neurites and blocking the vital
trafficking, and additionally releasing toxic peptides (see 145,146). In in vitro and in vivo models
of AD, even before the appearance of plaques in the brain, the presence of APP and BACE
cleavaged fragments of A42 have been shown to trigger autophagosomes to convert into as
endogenous source of A 147.
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2.4.5 A pathology
The cleavage and processing of APP can be divided into two pathways; a non-amyloidogenic
and an amyloidogenic pathway (see Figure 4). In the non-amyloidogenic pathway, a large
proportion of APP is cleaved on the cell  surface by -secretase producing an extracellular
soluble N-terminal fragment (sAPP) and a non-amyloidogenic carboxy-terminal fragment
of APP (APP-CTF/C83) 148.  This  in  turn is  cleavaged by presenilin-containing -secretase
(see 149) to yield a soluble N-terminal fragment p3 and a APP intracellular domain (AICD 150).
In the amyloidogenic plaque formation, the pathway follows a similar set of cleavages, but
instead  of  -secretase,  the  BACE  cleaved  fragment  of  APP,  APP-CTF/C99  is  further
processed in the endosomal compartments within the cell (see 151,152). Subsequently, after the
-secretase cleavage, the fragments of A40/A42 and  AICD  are  produced.  There  is  some
evidence indicating that the delayed AICD and A peptide accumulation may contribute to
the secondary changes in brain and worsen the post-ischemic outcome by increasing
neuronal death 153–158.
After  the  initial  amyloidogenic  cleavage  of  APP  into  A,  the  peptide  is  eventually
cleared from the central nervous system (CNS) via low-density lipoprotein receptor-related
protein 1 (LRP1) mediated pathway (see 159). In the periphery, the cleavage products of LRP1,
sLRP1s, sequesters the A in the plasma and transports it  to liver for further degradation.
The reverse transportation from periphery to CNS can occur with the help of transporters
such as receptor of advanced glycation end products (RAGE; see 160).
In  both  the  early-onset  and  late-onset  forms  of  AD,  the  4-kDa  A peptide  cleavage
product of two key enzymes reactions produced by - and - secretases has been considered
as  a  causal  factor  of  AD 50–52.  Previous  studies  with  mice  models  of  traumatic  brain  injury
have demonstrated that blockade of either - or -secretases can ameliorate motor and
Figure 4: Amyloidogenic and non-amyloidogenic APP pathways in a schematic picture.
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cognitive deficits and reduce cell loss 161. In early-onset AD, there is an increase in A cleavage
due to an inherited mutation in APP or presenilin (PSEN) 53. In late-onset AD, the elevated
enzymatic  cleavage  occurs  in  some  patients  who  have  a  high  level  of  BACE  caused  by  a
deficiency of microribonucleic acids (microRNAs) that control its expression 54. In addition,
a decrease in the A degrading enzymes may lead to late-onset AD 55. Different fragments of
APP were noted in astrocytes, neurons, oligodendrocytes, and microglia 12,91,162–166,  and  in
addition to brain, APP have been found all over the peripheral organs, e.g., heart, kidneys,
lungs, spleen and intestine (see 167).  The  fragment  size  of  A can  vary  between  39  and  43
amino  acid  residues,  with  A40 being  the  most  common  species  and  A42, a  longer,
hydrophobic  species  with  a  tendency  to  be  more  fibrillogenic.  Recent  studies  have
demonstrated that a soluble form of oligomeric A is more toxic than the monomeric form,
and consequently a conscious effort has been made to reconstitute oligomers from monomers
in the laboratory setting to demonstrate their toxicity in neuronal cells 96,168–171.
There is growing evidence to suggest that brain ischemia may play a role in the etiology
of late-onset AD. The calcium hypothesis postulates that there is an increase in the
intracellular calcium content as a response to A oligomer formation and this may lead to
neuronal  cell  dysfunction  and  death  in  AD 172. In vitro studies have further demonstrated
with human neuroblastoma (MC65) cells that the neurotoxicity of soluble A oligomers is
accompanied  by  a  marked  increase  in  the  intracellular  Ca2+ content 173. In addition,
memantine,  an antagonist  of  the  glutamate  activated calcium channel  NMDAR, improves
cognition and reduces  AD-like  neuropathology in  mouse model  of  AD and has  beneficial
effects in AD patients 174,175. Thus, treatments that interrupt aberrant Ca2+ influx may represent
promising therapeutic strategies for AD.
Additional research has demonstrated an interesting phenomenon, i.e., that human A
peptide removal/treatment is more effective in experimental ischemic brain injury in rats
176,177175,176 and less effective in mice with overexpressed A pathology 178. Furthermore, when
administered immediately after global ischemia, the secreted forms of APP proteins have
been  shown  to  exert  a  protective  effect  on  neuronal  injury  after  an  ischemic  insult 179. In
particular, sAPP has been shown to possess neuroprotective effect, rather than the
amyloidogenic pathways sAPP fragment 180,181. By activating K+-channels 182–184 and down-
regulating NMDAR 185 sAPP could  prevent  calcium  overload  in  the  neuronal  soma  via
reducing the  calcium load in  the  cells.  Other  possible  cascades  in  which APP may have a
protective role are by moderating hippocampal calcium responses to glutamate 186 and
inhibiting proapoptotic PSEN-1 mutant expression 187.
Altered APP processing indeed seems to play an important role in calcium homeostasis
and  this  may  lead  to  degeneration  in  AD 188.  Thus it has been speculated that altered
processing of APP could contribute to neuronal injury by compromising this normal function
of  soluble  APPs.  There  is  growing  evidence  that  APP  also  plays  a  role  in  other  crucial
processes like cell adhesion 189, cell proliferation 190 and neurite extension 191. Nevertheless,
the role of soluble APPs and the neuroprotective effects have recently suffered a setback due
to the fact, that excessive increase in sAPP may also shift proliferating cells toward
tumorigenesis and the activation of microglia may cause neurotoxicity. Another fact is that
at normal concentrations, A is indeed cleaved during brain embryogenesis and it seems to
be essential for normal brain development 192,193. Immunodepletion of the monomeric form of
A has  been  shown  to  cause  neuronal  cell  death  without  any  effect  on  a  variety  of  non-
neuronal cells 194.  There  are  other  important  beneficial  effects  of  monomeric  A,  e.g.,  an
increase in the survival hippocampal neurons and developing neurons, and protection of
neurons against excitotoxic cell death 195. Furthermore, A fragments have been reported to
play a major role as a guide in the transformation of the neural progenitor cells into neurons
(A40) or astrocytes (A42) 196.
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Recently, it was noted that neuropathological processes in ischemic neurons continue
well beyond the acute stage of insult 153,197–199. In these situations, the presence of a leaky BBB
200–203 probably leads to a risk that neurons in the ischemic area are made vulnerable to A
peptide 204.  In  addition,  A is  known to  causes  vasoconstriction and endothelium damage
205204, which in turn may reflect to the outcome in recirculation injuries occuring in the brain.
2.4.6 Dysregulation of cellular calcium homeostasis
Calcium is the major trigger of neurotransmitter release, a process that has been thoroughly
investigated during the past decades (see 206). Moreover, it has also become clear that calcium
is essential for a variety of other neuronal functions, including neuronal excitability 207,
integration of electrical signals 207,208, synaptic plasticity 209, gene expression 210, metabolism 211,
and programmed cell death 212.  In the thalamus, calcium has been shown to progress from a
diffuse distribution forming more dense and larger deposits with an overlapping pattern
with phosphorus after MCAO 213.
Free Ca2+ concentrations in the neuron. Under physiological conditions, intracellular
Ca2+ is tightly regulated, not only in the cytosol, but also within the organelles. Calcium
transporters, pumps and exchangers control the intracellular free Ca2+ concentrations against
a  huge  extracellular  calcium  gradient  difference  (Figure  5).  The  resting  free  Ca2+
concentration in the cytosolic milieu is approximately 0.1-0.2 μM, whereas it is 10 000-20 000-
fold higher in the extracellular space 214,215.  The majority of the intracellular Ca2+ (< 99%) is
bound to cytosolic proteins or stored in ER. The ER holds significant amounts of free Ca2+ in
its lumen, and even in the resting state, the concentration of free Ca2+ in ER is 500-5 000-fold
higher than that in the cytosolic space 215–217. Similar gradients of Ca2+ can be also stored in the
GA,  which  functions  in  close  collaboration  with  ER 215,216. Under normal conditions,
mitochondria do not act as calcium storage sites, but however, after stimulation, they are able
to rapidly accumulate large amounts (up to 80 μM) of calcium (see 218,219).
Plasma membrane, influx. Calcium influx  into  dendrites  and  the  soma  is  largely
dependent on presynaptic neurotransmitter release and the membrane potential, with the
latter being mainly controlled by Na+ and K+ -channels 220. Channels in the plasma membrane
allow passive Ca2+ influx  down  an  electrochemical  gradient.  There  are  two  main  channel
types which have been categorized based on the movement-control mechanism; voltage-
dependent calcium channels (VDCC) and ligand binding gated calcium channels (see 221). In
particular, glutamate receptor family members are known to mediate exitotoxicity in the
cells. The activation of ionotropic glutamate receptors NMDA, AMPA and kainate leads to
an enhanced permeability to Na+, K+ and/or Ca2+ in the associated ion channels 222,223, and thus
plays a crucial role in the Ca2+ influx.
Plasma membrane, efflux. Two major plasma membrane mechanisms are responsible
for the extrusion of calcium from cells.  One is the ATP-driven plasma membrane calcium-
pump  (PMCA),  the  other  is  the  Na+/Ca2+ exchanger  (NCX),  a  complex  similar  to  that
responsible for the removal of Ca2+ from the mitochondrial matrix into the cytoplasm 224–226.
Unlike mitochondria, plasma membrane NCX has the inherent ability to move Ca2+ into or
out of the cell depending on the prevailing conditions. There are reports that the loss of
PMCA function (for example dysfunction of the calcium binding protein calmodulin 227)
causes  an  increase  in  the  intracellular  Ca2+ levels  and  this  can  trigger  apoptotic  death  of
cerebellar and spinal cord neurons 228. Transient receptor potential cation channels, subfamily
M, members 2 and 7 (TRPM2 and TRPM7) are non-selective ions channels, which have been
shown to become activated in ischemic conditions and mediate oxidative stress-dependent
cell death 223,229. Interestingly, TRPM7 is believed to regulate cell adhesion via calpain
mediated influx of Ca2+ 230.
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Neuronal Ca2+ homeostasis, intracellular. The  ER  is  a  complex  system  of
endomembranes  and  it  is  present  in  all  neurons  extending  from  the  nucleus  to  the  soma,
dendrites,  and dendritic spines, and down the axons to the presynaptic terminals.  The ER
can  act  as  a  dynamic  calcium  store,  accumulating  calcium  and  releasing  it  in  response  to
physiological stimulation. Within the ER, Ca2+ binds  to  molecular  chaperones  such  as
calreticulin and calnexin (see 231).  In  neurons,  Ca2+ exits  from  the  ER  mainly  through  the
isoforms of inositol triphosphate receptors (IP3Rs)  and  the  Ca2+ activated isoforms of
ryanodine receptor (RyR), both of which are large tetrameric channel proteins 221. Store-
operated calcium entry (SOCE) refers to an ER operated influx of extracellular calcium across
the plasma membrane. Recently, this calcium entry mechanism has been demonstrated to
occur following cerebral ischemia and contribute to neuronal death 232. In addition to its
known functions  in  processing and sorting of  lipids  and proteins 233, the Golgi Apparatus
(GA) is also known to play a role as an intracellular calcium store, in conjunction with the ER
234–236. Ca2+ homeostasis  in  the  intracellular  golgi  is  regulated  by  two  groups  of  pumps:
sarco/endoplasmic reticulum calcium ATPases (SERCAs) and secretory-pathway calcium
ATPases (SPCAs) 237. The relative contribution of SERCAs and SPCAs to the total uptake of
Ca2+ into the GA seems to be cell-type-dependent, for example, the highest dependence of
SPCAs occurs in human keratinocytes 238. One of the main functions of mitochondria is to
produce nicotinamide adenine dinucleotide and ATP, but it is also now well accepted that
this organelle also acts as a Ca2+-buffer. Mitochondrial Ca2+  buffering is more efficient than
can be achieved by expelling Ca2+  through the plasma membrane or into the ER, and thus
this mechanism is considered to be very relevant for neurons 239. In a crisis situation such as
during ischemia there are high demands for mitochondria-derived ATP. Because of the low
ATP/adenosine diphosphate (ADP) ratio in the ischemic core, additional Ca2+ is released,
which in turn, activates enzymes in the Krebs cycle, thus causing a boost in ATP production
240. In mitochondria, the majority of Ca2+ is expelled via mitochondrial NCX (mNCX). A
secondary route to Ca2+ to traverse to cytosol occurs via the proton/Ca2+ exchanger (MPT pore)
241. In addition, lysosomes have been shown to act also as a component of the Ca2+ buffering
system in the cell by storing any excess calcium 242.
Ca2+ buffers and sensors. In addition to the cell organelles mentioned above, also a
large  set  of  proteins  can  act  as  buffers  and  sensors  needed  in  the  maintenance  of  Ca2+
homeostasis. For example, EF-hand Ca2+ -binding domains (for more information see 243) can
possess both buffering and sensoring functions. Calmodulin serves as a Ca2+ sensor, instead
calretinin, calbindin and parvalbumin seem to function as buffers.  Another group of Ca2+ -
binding proteins are called intracellular neuronal Ca2+ sensors (NCS; see 244). When
considering  about  ischemia  and  AD  linkage,  the  most  interesting  NCS  subfamily  is  the
potassium channel interacting protein 3, coding calsenilin, which has been shown to interact
with presenilin 1 (PSEN-1) and 2 (PSEN-2; see 245).
Intracellular Ca2+ removal. Unlike calcium influx, calcium clearance requires ATP,
which may originate from either glycolysis or mitochondria. PMCA, mMCA and SERCA are
especially dedicated to removing calcium ions against an electrochemical gradient, and these
processes require hydrolysis of ATP in order to work. Recent studies have shown that excess
calcium within neurons is removed especially via PMCA and it is powered by glycolysis 246.
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2.4.7 Dysregulation of axonal calcium 
Focal cerebral ischemia in the cortex evokes inflammatory responses in perilesional areas. 
The thalamus is spared from acute ischemic damage because it receives a blood supply 
through the posterior cerebral artery. Nevertheless, due to its synaptic connections, signs of 
delayed damage in various thalamic nucleus are obvious as neuronal loss and atrophy are 
seen weeks after the onset of the stroke 80,117. This is thought to be due to the loss of GP and 
the effect of this loss in the glutamatergic and GABAergic pathways innervating the cerebral 
cortex and thalamus 110. The microglia activation and both anterograde and retrograde 
degeneration  lead to severe thalamic atrophy after ischemia 247 (see Figure 6 and 248).   
Figure 5: Representative picture of calcium channels and concentration in a cell. The intracellular
calcium concentration may be over 10 000 to 20 000 times smaller than in extracellular space. 
Especially endoplasmic reticulum and mitochondrias store excess calcium in the intraorganelle
spaces. Transmembrane transporters and channels; transient receptor potential cation 
channel, subfamily M, member 2 (TRPM2), transient receptor potential cation channel, subfamily 
M, member 7 (TRPM7), voltage dependent Ca2+ channel (VDCC), plasma membrane Ca2+ ATPase
(PMCA), Na+/Ca2+ exchanger (NCX), store-operated calcium entry (SOCE). Excitatory amino
acid receptors; 2-amino-3-3(3-hydroxy-5-methylisox-azol-4-yl) propionate receptor (AMPAR), 
N-methyl-D-aspartate receptor (NMDAR), Kainate receptor. Endoplasmic reticulum (ER);
sarco/endoplasmic reticulum Ca2+ ATPase (SERCA), inositol triphosphate receptor (IP3R),
ryanodine receptor (RyR). Mitochondria (MIT); mitochondrial Na+/Ca2+ exchanger (mNCX),
mitochondrial membrane Ca2+ ATPase (mMCA), uniporter, mitochondrial permeability transition 
(MPT) pore. [Ca2+]EXT: extracellular, [Ca2+]INT: intracellular, [Ca2+]ER: endoplasmic reticulum and 
[Ca2+]MIT: mitochondrial calcium concentrations. 
16
Special emphasis on Na+/Ca2+ exchanger. NCX is the main calcium export mechanism
across  the  plasma membrane and it  is  responsible  for  restoring the  resting level  of  Ca2+ in
neurons after stimulation. Two families of NCX have been found, of which one requires the
co-transport of K+ (NCKX).  NCKX is  rather  less  understood,  but  it  does  seem to  be  a  less
important factor in the acute calcium overload in the cells (see 249,250)
NCX is a nine transmembrane segment protein which is widely distributed in the brain
251250. It functions in a bidirectional way, coupling the movement of Ca2+ and Na+ ions across
the cell membrane in the CNS. NCX has also been found in the inner membrane of the nuclear
envelope and has been proposed to mediate Ca2+ flux  between  the  nucleoplasm  and  the
nuclear envelope 252 and then to the ER 253.
Under normal conditions, NCX is the main pathway for calcium efflux, but it can also
contribute to Ca2+ influx (reverse mode exchange), especially during intense depolarization,
and with increased intracellular sodium (see 62). The affinity for calcium and its high capacity
make NCX suitable for the rapid clearance of large amounts of calcium without the need of
ATP hydrolysis 254. Thus, NCX may act as a protective mechanism against Ca2+ overflow 255.
Figure 6: Representative picture of acute axonal injury modified from Stys 2005 247. Area
presented in white background illustrates the pathways described at the cellular level in this
thesis. Energy deficit causes impairment in ATP-dependent Na+/K+–pumps in cell membrane
(1a).  The  rise  of  intracellular  sodium  (Na+) (3a) and potassium (K+) (3b), stimulates the
Na+/Ca2+ exchanger (NCX) to operate in the reverse Ca2+ import  mode  (4).  This  Ca2+
accumulation (5) promotes destructive events including mitochondrial Ca2+ overload (6),  and
over-activation of several Ca2+-dependent enzyme systems (7).
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NCXs  are  presented  in  three  different  forms  (NCX1,  NCX2  and  NCX3),  with  NCX3
being mostly presented in subpopulations of neurons, where it is localized predominantly in
dendrites, and distal astrocyte processes that contact excitatory synapses 256. In the cerebral
cortical areas, the NCX1 isoforms are highly expressed in pyramidal neurons of layers III-V.
In addition, NCX1 protein is mainly detected in the hippocampus, in the hypothalamus, in
the substantia nigra, in the ventral tegmental area, and in the granular layer of cerebellum.
In the same study, NCX2 was expressed mainly in somatosensory cortical areas, but also in
hippocampus, thalamus and hypothalamus. NCX3 protein was found particularly in the
hippocampal subregions and in ventral striatum and cerebellar molecular layer 251.
Interestingly, transcription of the NCX1 gene is controlled by three separate promoters and
it  is  independent  of  calcium  levels,  but  in  contrast,  NCX2  and  NCX3  genes  are  strictly
dependent on calcium levels, although in different and reverse manners (see 250).
Studies with transgenic and knockout animal models have revealed that animals
lacking the NCX2 isoform exhibits an improvement in several hippocampal-dependent
learning and memory tasks 257. In addition, animals lacking the NCX3 gene display reduced
motor activity and weakness in their forelimb muscles 258. The homozygous NCX1 knockout
experiment lead to non-viable embryos, possibly due to failure of the foetal heart to beat 259.
The NCX3 dysfunction has been connected also to overproduction of A and oxidative stress
activated calpain 260 and caspase 261,262. It has also been shown that aggregated A peptides
could interact with the hydrophobic intracellular loop of the exchanger inhibiting its calcium-
extruding functions 263.  A  great  many  other,  some  partly  conflicting,  reports  have  been
published about the effect of NCX modulation on cell damage 264–268. For example, NCX
blockade worsens infarction volumes in rodent models of focal cerebral ischemia 269. In
contrast,  there  are  also  reports  in  which  a  NCX  inhibitor  has  been  able  to  reduce  infarct
volume in animal stroke models 270,271.
One possible explanation for these controversial results may be traced to the fact that
after ischemic hypoxia/anoxia, the expression of these three genes is differentially regulated.
As explained by Gomez-Villafuertes et al 250, there is a massive downregulation of NCX2 after
cerebral  artery  occlusion  and  at  the  same  time  there  is  an  increase  in  accumulation  of
messenger RNAs of NCX1 and NCX3 in the peri-infarct brain area, as well as in non-ischemic
surrounding areas, leading to the conclusion that the putative neuroprotective effect may be
attributable to NCX1 and NCX3 gene products rather than emanating from NCX2. Another
explanation for some of these variations in outcome could be due to the differential NCX
responses in the ischemic area; in mild injury where Na+/K+ ATPase is preserved, blockade
of  NCX  prevents  normal  Ca2+ extrusion  from  the  cell.  In  contrast,  in  areas  where  ATPase
activity is severely reduced, the elevated intracellular Na+ load evokes NCX to operate in its
reverse  mode  as  a  Ca2+ -influx  pathway,  and  under  these  conditions  a  blocking  of  NCX
channel would be protective. Earlier studies have already provided some insights into the
different expression of the three subtypes of NCX after focal cerebral ischemia 272 laying the
foundations for future interventions with NCX inhibitors. For a more detailed review about
NCXs, see Annuziato et al 273.
2.4.8 A and calcium interaction
One interesting phenomenon which can be observed days after the ischemic insult in rodents
has been the overlapping accumulation of A and calcium in the thalamus 92,213,274.  It  is
difficult to conduct studies evaluating the temporal pattern, e.g., which one is the first to be
activated, since it entrails gathering data separately from both stroke and AD studies.
In  a  study  done  in  our  laboratory,  APP/A activation  in  the  thalamus  was  seen  one
week after ischemia and it persisted for up to one month in rats, whereas in the same study
also calcium and increased activity of BACE, insulin-degrading enzyme (IDE) and NEP were
observed in the thalamus 9. These results are in line with concept that increased BACE activity
may result from caspase-3 mediated cleavage of Golgi-localized -ear-containing ARF
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binding protein 3 (GGA3), which under normal conditions inhibits the excessive activity of
BACE in the APP-cleavage pathway 275. On the other hand, Ca2+ released from ER has been
shown to be crucial in the activation of caspase-3 276, which would suggest that an increase in
Ca2+ -levels in the cell is the primary factor underpinning the BACE overexpression.
Additional support for the hypothesis that Ca2+ is the initial trigger for dysfunction in
APP/A clearance is, that already three days after the ischemic insult, calcium accumulates
in the VPN thalamus 132. Related to the dysfunction of thalamo-cortical signaling after stroke,
a study from Zhang et al.,  showed that axonal swelling is detectable already 6 hours after
ischemia  in  rats  and  this  persisted  for  up  to  4  months,  but  neither  A plaques  nor
overexpression of A42 were seen within and/or close to the swollen axons 277. In addition,
activation of tau phosphorylation was observed at 6 hours after ischemia in the same brain
areas, but this declined at the later time points 277. Similar changes have been reported in the
thalamus two days after ischemia 108.
In short,  the primary changes encountered after ischemia at the cellular level are cell
swelling, which in turn with the increase of Na+ allows Ca2+ to flood into the cell. This may
interact with other overlapping pathologies such as the increase in the NO levels increases
caspase-3 activities, leading to a vast supply of BACE and this would bias the APP processing
into the amyloidogenic direction.
In contrast to the primary changes occurring in the brain after ischemia, long follow-up
studies  have  shown  that  the  diffuse  N-  and  C-  terminal  APP  and  A deposits  have
disappeared in the cortical areas at one month after an experimental stroke, but instead the
deposits in the thalamus start to accumulate 92. At the timepoint 9 months after ischemia,
neither APP nor A was seen in the cortical areas, but in the thalamus, the deposits had been
transformed into plaque-like deposits containing only N-terminal APP and A. In the same
study, acute activation of astrocytes and microglia was detected in the border of ischemic
area.  After  one  month  the  number  of  activated  glial  cells  had  decreased  and  totally
disappeared after nine months. However, in the VNP, the time course of glial activity was
quite different; one week after MCAO very few microglia cells and astrocytes were present.
In contrast, after one month a large number of microglial cells and astrocytes were present in
the same area. After 9 months, the A deposits were surrounded by an astroglial scar, and
there were no activated microglia present 92.  An even longer follow-up from Iwata et al 278
revealed that one year after a traumatic brain injury there was still accumulation of A.
Dysregulation of Ca2+ in AD. In  AD,  the  accumulation  of  oligomeric  species  of  A
protein and neurofibrillary tangles in the brain are considered to be key factors that cause the
disease. It has been postulated that excessive release of A incorporates into neuronal
membranes, forming calcium-permeable channels, thus increasing the intracellular calcium
concentration 279–281.
Studies with young and old rodents have shown that neuronal calcium-regulating
systems undergo many age-dependent changes. These include elevated intracellular calcium
levels, increased calcium influx through VDCCs, enhanced calcium release from intracellular
stores through IP3R and RyR, reduced contribution of NMDAR-mediated calcium influx,
impaired ability of mitochondria to buffer or cycle calcium, reduced cytosolic calcium
buffering capacity and activation of calcineurin and calpains (see 282).
There is evidence from both in vitro and in vivo studies indicating that A can trigger
Ca2+ influx  through  endogenous  membrane  channels,  usually  via  the  NMDAR 283.  In
addition, other data suggests that calcium influx through synaptic NMDAR can promote
non-amyloidogenic APP processing, leading to the formation of the beneficial sAPP 284.
Another  hypothesis  is  that  VDCCs  can  be  activated  by  A in  the  early  phase  of  AD
pathogenesis (see 285) thus elevating the intracellular calcium levels. Furthermore, presenilin
proteins  which  are  involved  in  AD  pathogenesis,  are  located  in  the  ER  and  if  they  are
dysfunctional, there can be leakage of Ca2+ into the cytoplasm or they may interact with RyR,
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IP3R, and SERCA to increase their activity 286–290. Interestingly, in the study of Kuchibhotla et
al., A deposits were required in order that they could induce calcium overload in transgenic
mouse model of AD 291,  which  emphasized  that  the  presence  of  oligomeric  A fragments
would lead to dysfunction in calcium homeostasis in the neuron, not vice versa.
A more recent study demonstrated that especially the NCX subtype NCX3 functioning
through calpain activity has a major impact on A42 toxicity in the AD brain 292. The review
of  Yu  et  al 282 evaluates several possible mechanism through which A could stimulate
calcium uptake. In general, most of the A fragment targets are ER and mitochondria-related
channels and receptors, which in turn could well evoke an increase in the intracellular Ca2+
level.
2.5 ANIMAL MODELS TO STUDY STROKE
2.5.1 STAIR guidelines for stroke research
The  Stroke  Therapy  Academic  Industry  Roundtable  (STAIR)  recommendations  were  first
time published in 1999 to improve the quality of preclinical stroke studies 293,294. Although
over a decade has elapsed, the implementation of these guidelines into practice has been a
slow process.
The  main  concerns  highlighted  in  the  STAIR  recommendations  are  the  appropriate
selection of animal models and conducting good quality research including randomization,
study inclusion/exclusion criteria and power- and sample-size calculations. In addition, it is
recommended that studies should be conducted also in old animals, in both sexes, and in
animals with co-morbidities like hypertension and diabetes. If one wishes to adequately
assess the treatment efficacy, then clinically relevant biomarker-data should be collected
from multiple time points and also from longer follow-up studies.
The use of primates in stroke research is included in STAIR recommendations. After
initial testing of treatment efficacy in rodents, non-human primates or large animals should
be included in the studies before embarking on clinical studies. The guidelines also recognize
the cost, availability and ethical problems related to use of primates 293,294.
2.5.2 Brain – comparison from mouse to human
Before new drug compounds can be tested in humans, large amounts of preclinical studies
have to be conducted. Most of the preclinical in vivo studies are conducted with mice (Mus
musculus; over 7 million mice were used in EU in 2008) and rats (Rattus norvegicus; over 2
million).  For  comparison,  only  904  non-human  New  World  monkeys,  such  as  common
marmosets (Callithrix jacchus) were used in preclinical studies 295.
However, quantity is not synonymous with better impact, in terms of translation of the
data.  For  comparison,  the  mouse brain  weighs  approximately  0.4  grams,  the  rat  brain  is  2
grams,  the  common  marmoset’s  brain  is  8  grams  whereas  the  human  brain  weighs
approximately 1500 grams 111,296–300.  Thus  the  difference  between  mouse  and  human  brain
weight is 3750-fold. Furthermore the number of neurons differs, from mouse’s 75 million to
a human’s 86 billion 301–304. It is noteworthy that the common marmoset has a similar
distribution of neuronal and glial cells in the brain compared to the human brain 304.  There
are also the gray/white matter ratio differences between the species 296,305.  See  Table  1  for
summary.
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2.5.3 Different ischemia models
One needs valid experimental models if one wishes to understand the basic mechanisms of
ischemic damage and functional recovery. Relevant animal models are essential in the
development of new therapies. Rodent models for stroke are most commonly used due to
the similar vasculature to humans, low costs,  vast supply of different behavioral tests and
imaging opportunities.
The majority of all the human strokes are ischemic, and the MCA is the most commonly
affected vessel in stroke. Spontaneous reperfusion occurs in the majority of untreated stroke
patients during the first week after the onset of symptoms 306. One of the most widely used
reperfusion models in rats is transient middle cerebral artery occlusion using a filament 307.
In this model, a intraluminal thread is inserted into the internal carotid artery through the
external carotid artery in order to block blood flow to the MCA territory. The filament is
removed after 60 to 120 min thus allowing reperfusion. The model is invasive and the animals
require post-operative care.
Table 1: Comparison between the laboratory animals and human. Estimate means are collected
from the references mentioned in the text 2.4.2.
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Permanent  ischemia  can  be  produced  by  either  the  proximal  (Tamura  model)  or  the
distal  MCAO.  In  the  Tamura  model,  the  proximal  regions  of  the  MCA  are  first  exposed
through a craniotomical window next to the olfactory tract, and then the artery is occluded
by electrocoagulation. As a result, an extensive neocortical and striatal infarct is produced,
and this is associated with persistent sensorimotor and cognitive deficits 268,308,309. In the distal
MCAO model, the artery is occluded through a small burr hole made between the eye and
external auditory canal 310. In order to produce a consistent lesion in normotensive rats, the
ipsilateral common carotid artery has to be occluded permanently or both common carotid
arteries transiently from 45 to 60 minutes. This model causes a frontoparietal cortical lesion,
while  the  subcortical  structures  are  spared.  In  contrast  to  the  proximal  MCAO  occlusion
model, partial recovery in sensorimotor deficits can be seen over time 308–312. The weight loss
and feeding difficulties encountered after the operation are less severe compared to those
found with the filament model.
Endothelin-1 (ET-1) is a potent vasoconstrictor that has been used to produce ischemic
injury.  In  this  method,  the  animal  is  placed  into  a  stereotaxic  frame  and  endothelin-1  is
injected adjacent to the MCA resulting in a rapid blood flow with the artery only reopening
hours later 313. In order to achieve an irreversible injury in the brain, after the ET-1 injection,
the CBF has to decline significantly (~50 ml/100 g/min) and to stay below 100 ml/100 g/min
for at least 10 hours 314. In this stroke model, a typical injury occurs in the lateral cortex and
dorsolateral striatum, while the forelimb motor cortex is spared. Missing hyperthermic
response  and  less  vascular  invasive  method  are  the  major  advantages  of  this  model
compared to the intraluminal methods. The correct placement of the ET-1 is the most
common technical difficulty encountered with in this model, and this may account for much
of the variability in the success rate.
Photothrombotic models are one of the less invasive models to produce stroke in rats
and mice. Photothrombosis requires the use of photosensitive dyes like Rose Bengal or
erythrosine B to cause intra-arterial endothelial irritation and eventually a formation of the
thrombus and occlusion 315–317. In this model, the animal is placed into a stereotaxic frame and
the skull is exposed. After the intravenous injection of the photosensitive dye, a cold white
light or a laser beam is targeted to the cortical area of interest. Skull thickness, time of the
illumination and concentration of the dye will determine the severity of the cortical lesion.
Photothrombotic lesions are characterized by occlusion of small cortical vessels, small
penumbral area and diminished collateral blood flow. Infarcts are consistent with a precise
location and size. Other advantages of photothrombotical models are the low mortality of
animals and high success rate.
Embolization is an attempt to mimic the formation of the thromboembolic stroke in
animals. The embolus is achieved after an injection of microspheres, macrospheres, clot or
purified thrombin into the internal carotid artery 318–321. The major problem is high variability
limiting a more general use of these models.
In larger animals which have larger vascular volumes, the stroke models are more
limited. For example in rabbits, a transient model occluding the MCA was developed for
testing the tPA efficacy already in the early 1980s 322. Different embolic methods have also
been used in awake animals, enabling real-time behavioral testing while occlusion is
developing 323. There are some stroke models which better resemble the human brain
structure and vasculature using gyrenecephalic animals, like pigs, sheep, cats, dogs and non-
human primates.  The primary difficulty  with  using these  animals  are  the  cost  and ethical
issues. In addition, their large size usually requires a more mechanical approach to produce
the occlusion. Similar to the rabbit studies, also in gyrenecephalic animals, the most common
way to produce the clot is to utilize an embolic method (see 324).
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Due to their analogous vascular system, one could hypothesize that the non-human
primates would be by far the most appropriate subjects in which to study the pathology of
stroke. Embolic models have been used also in non-human primates 325–327, although open
surgery occlusion models have greater precise in location and size (see 328). Recently also a
transient filament model has been described for the stroke studies using common marmoset
329,330.
2.5.4 Behavioral tests to study stroke
In humans, a large MCA territory infarct causes neurological deficits, such as contralateral
hemiplegia affecting the face, arm and the leg. This is also associated with a loss of superficial
and deep sensations. In addition, one can encounter major higher function disturbances,
including aphasia, visuopatial impairment, and hemineglect 331.
Rats having a focal cerebral ischemia after MCAO have been shown to exhibit deficits
in several tests assessing sensorimotor and cognitive functions 332. In contrast to memory and
learning tasks, brain ischemia does not seem to result in long-lasting neurological deficits in
alertness nor in sensimotor capacities 333. However, with more demanding behavioral
outcome  measures,  then  functional  deficits  can  be  revealed  even  a  long  time  after  the
ischemic insult 334–336. Depending on the model selected to mimic the ischemic conditions,
different behavioral tests can be used to follow the recovery.
The  ischemic  rats  are  impaired  in  tests  which  assess  coordination  and  integration  of
motor movement, such as beam walking 337,338 and the grid-walking test 339. Similar foot-fault
measurements can be attained with a rotating wheel 340. Montoya’s staircase test measures
skilled coordination of the forelimb in the ability to reach and grasp food pellets from
different distances 341,342.  The  limb  placing  test  can  be  used  to  measure  the  hindlimb  and
forelimb responses to tactile and proprioceptive stimulation 343–345.  The cylinder test can be
used to assess asymmetry in the use of forelimbs in the lateral movements against the
cylinder wall 346,347.
In addition to sensorimotor dysfunction, cognitive deficits following focal cerebral
ischemia have been found in tests measuring associative memory such as passive avoidance
348–351 or spatial memory such as water maze 352,353 and radial arm maze 354,355.
If one wishes to assess true neurological recovery instead of compensation (such as the
use of the tail as an aid when the animal is performing the beam walking and Rotarod test)
or adaptation (as can occur in cylinder test when the test is repeated multiple times within a
short time period), then a battery of different behavioral tests should be selected for
preclinical testing. A well designed test battery with cross validation of the observations is
more powerful than any single test.  In addition, high speed video recording for frame-by-
frame analysis can be useful in differentiating between compensatory mechanisms and true
recovery 356.
It is challenging to distinguish between primary neurological deficits and those induced
by secondary changes. The extend of thalamic atrophy in MCAO rats has been demonstrated
to correlate with the late sensory deficits revealed through the adhesive-removal test and in
other tests measuring skilled forelimb function 336,357. Studies with human APP (hAPP)
transgenic animals with an excessive A load in the thalamus have also shown sensorimotor
deficits compared to wildtype littermates 358.
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2.6 TREATMENTS TO PREVENT THE SECONDARY PATHOLOGY
As previously  mentioned,  only  a  subpopulation of  patients  benefit  from the  US FDA and
EMEA approved tPA treatment for stroke because of the strict therapeutic time window (<4.5
hours). Surgical interventions and manual removal of the intravenous clot require highly
specialized hospitals and surgical staff. In contrast, the secondary pathology in the brain
offers a completely different time window for treatment. However, insufficient attention has
been paid to the secondary pathological changes.
Pharmacological studies have revealed that delayed administration of various drugs
prevents  ischemia-induced pathology in  thalamus,  which in  turn is  reflected in  improved
sensorimotor or cognitive functions 142,359–362. Different pharmacological approaches have
been attempted to target this secondary neurodegeneration. For example, ciliary
neurotrophic factor (CNTF) treatment after distal permanent MCAO has reduced the
neuronal loss and improved cognitive water-maze performance 360. The inhibitor for protein
synthesis  (CHX) after  a  permanent  MCAO was also  found to  decrease  neuronal  death 132.
Treatment after transient MCAO with the iron chelator deferoxamine was claimed to
decrease infarct size, to prevent thalamic shrinkage and to improve the behavioral recovery
363. Similarly carbamylerythropoetin lessened inflammation markers and improved
behavioral outcome 21. An antagonist for axonal outgrowth inhibitor receptor, Nogo-66
(NEP1-40) has been shown to lessen the axonal injury and to prevent axonal degeneration
after permanent MCAO 364.  In addition, treatment with a -secretase inhibitor (DAPT) has
been shown to prevent secondary damage after permanent MCAO by decreasing levels of
A, gliosis and neuronal loss in the thalamus leading to improvements in behavioral tests
assessing sensory functions 362.
Another striking feature of secondary pathology after stroke is its similarity to AD. This
raises the possibility that one can use experimental stroke as a model with which to study
AD pathology and therapies. Current treatment for AD includes symptomatic drugs, which
have  only  modest  efficacies,  and  none  of  them  have  shown  any  ability  to  reverse  the
underlying progression of the disease. Nevertheless, several lines of evidence have indicated
that calcium dysregulation plays a major role in both in the pathogeneses of AD and stroke
62,172,365–367.
2.7 RATIONALE
There  are  many  studies  which  have  been  conducted  ranging  from  preclinical  to  clinical
studies  in  stroke  and  AD.  However,  only  a  few  studies  have  examined  calcium  and  A
accumulation in the thalamus and even fewer studies have investigated whether preventing
this  type  of  secondary  pathological  changes  in  the  brain  could  be  reflected  in  a  better
functional outcome. Therefore, in the present thesis, the author has focused on the secondary
pathology in the thalamus affected by inflammation and calcium dysregulation after stroke.
Inflammation is known to be a major contributor to the pathological changes in the
brain during acute and chronic phase of stroke. In addition, excessive calcium accumulation
into cells after stroke has been shown to be lethal to nerve cells and cause axonal dysfunction.
Synaptic dysfunction and transportation deficits may lead to additional A accumulation in
the brain and again increase the neuronal loss occurring after stroke.
Given this background, this thesis examined whether the inflammatory effect in the
thalamus could be ameliorated by chronic ibuprofen treatment, and whether inhibiting
calcium accumulation in the cells with bepridil  or KB-R7943 could improve the functional
outcome after experimental stroke.
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In addition, much less is known about the stroke-related thalamic pathological changes
present  in  species  genetically  more  close  to  humans.  In  accordance  with  the  STAIRs
recommendations about the use of multiple species, this thesis investigated the changes
present in the thalamus after experimental stroke in marmosets.
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3 Aims of the study
The aim of the study was to understand secondary pathology in the thalamus following
stroke and to test pharmacotherapies which would target these pathological mechanisms.
The specific aims included:
1. To test the effect of the non-steroidal anti-inflammatory drug, ibuprofen, in chronic
stroke in rats and to measure the outcome via behavioral tests and histological
analyses.
2. To  prevent  calcium  accumulation  after  stroke  in  the  rat  brain  by  chronic
administration of the non-selective calcium channel inhibitor bepridil, or an inhibitor
of the reverse Na+/Ca2+ exchanger, KB-R7943, and to follow the behavioral, histological
and molecular outcomes.
3. To investigate the interaction between calcium and A accumulation in the thalamus
by  inducing  a  cortical  lesion  in  AD  mice  and  treating  the  animals  with  the  non-
selective calcium channel inhibitor, bepridil.
4. To study whether there is similar pathology occuring in non-human primates after an
experimental stroke.
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4 Materials and methods
4.1 ANIMALS AND HOUSING CONDITIONS
4.1.1 Rats (studies I, II and III)
A total of 116 (study I: 40, study II: 31, study III: 45) male Wistar rats (age 2-3 months) from
the Laboratory Animal Center, Kuopio, Finland, weighing 251-384 g were subjected to either
MCAO or a sham-operation. The rats were housed individually under 12:12 hour light/dark
cycle in a temperature controlled environment (20 ± 1 °C), with food (2016, Teklad) and water
available ab libitum. All animal studies were approved by the Animal Ethics Committee
(Hämeenlinna, Finland) and conducted in accordance with the guidelines set by the
European Community Council Directives 86/609/EEC. All efforts were made to minimize the
number of animals used and to ensure their welfare throughout the studies.
4.1.2 Mice (study IV)
A  total  of  63  male  transgenic  mice  that  overexpress  human  APP  (hAPPSL) within a
C57BL/6xDBA background, and their non-transgenic littermates, were used in this study at
an age of 4-5 months (QPS Austria, former JSW Lifesciences, weight 25.9-46.7 g). There was
no human A-positive staining in the wildtype mice, thus confirming the phenotype. The
mice were housed in ventilated cages on standardized rodent bedding material
(Rettenmaier®). Each cage contained a maximum of five mice. The mice had free access to
food (Altromin®) and water throughout the experiment and were housed on a 12-hour light
cycle in a temperature-controlled environment (24 °C, humidity 40-70 %). All animal
procedures  were  approved  by  the  Styrian  Government,  Austria,  and  conducted  in
accordance  with  the  guidelines  set  by  the  European  Community  Council  Directives
86/609/EEC. All efforts were made to minimize the number of animals used and to ensure
their welfare.
4.1.3 Marmosets (study V)
A total of six male or female common marmosets from the breeding center at the University
of Caen were used (age 22-30 months, weight 280-360 g). All procedures were performed
according to the European Directive (86/609/EEC) and approved by the Regional Ethics
Committee.
4.2 STUDY DESIGNS
Figure 7 is an overall picture of the study designs. The behavioral tests are described in detail
in section 4.4. The animals were habituated to the laboratory environment and handling well
before the projects began.
Drug administration. In studies I, II, III and IV, per os -drug administration was started
on post-operative day 2 and continued once a day until the euthanasia of the animals.
Imaging. In study V, the marmosets went through MRI on post-operative day 7.
Euthanasia. All animals were perfused for histological analysis. In studies I, II and III
euthanasia was performed on day 29. Mice in study IV were perfused on day 30. Marmosets
were perfused on day 45 after the MCAO.
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4.3 EXPERIMENTAL STROKE MODELS
4.3.1 Filament model (studies I, II, III and V)
Rats: Focal cerebral ischemia was induced by the intraluminal filament technique 307.
Anesthesia was induced in a chamber with 5 % halothane in an O2/N2O mixture (30 %/70 %).
A surgical depth of anesthesia was maintained throughout the operation with 0.9-1.3 %
halothane delivered through a nose mask. Body temperature was monitored and maintained
at 37 °C using a heating pad connected to a rectal probe (Harvard Homeothermic Blanket
Control Unit, Harvard Apparatus).
The right common carotid artery was exposed through a midline cervical incision under
a surgical microscope and gently separated from the nerves. The external common carotid
artery was closed with a  suture  and cut  with  microscissors.  A heparinized nylon filament
(diameter 0.25 mm, rounded tip) was inserted into the stump of the external common carotid
artery. The filament was advanced 1.8-2.1 cm into the internal common carotid artery until
Figure 7. Study designs.
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resistance  was  felt.  The  filament  was  held  in  place  by  tightening  the  suture  around  the
internal common carotid artery and placing a microvascular clip around the artery.
After 120 min (studies I and II) or 90 min (study III) of MCA occlusion, the filament was
removed and the external carotid artery was permanently closed by electrocoagulation. The
sham-operated rats were treated in a similar manner, except that the filament was not placed
into the internal carotid artery. Buprenorphine (0.03 mg/kg, subcutaneous injection, s.c.) was
used to relieve postoperative pain. In addition, postoperative care of MCAO rats included
supplemental 0.9% NaCl (intraperitoneal injection, i.p.) and softened food pellets to prevent
weight loss.
Marmosets: Focal cerebral ischemia was induced using the intraluminal filament
technique as described previously 329,330,368. Anesthesia was induced with isoflurane (5%) and
maintained during the entire experiment with isoflurane (1% to 1.5%) in an O2/N2O mixture
(30%/70%). The animals were orally intubated and mechanically ventilated (Harvard
Apparatus).
Briefly, a nylon thread, with a distal cylinder of 3mm length and 0.54mm diameter,
was inserted into the external carotid artery and gently advanced up to the origin of the MCA
(approximately 27 mm from the bifurication between internal carotid artery and external
carotid artery. The thread was removed after 3 h in MCAO animals (n=4, 3 male/1 female) or
immediately in the sham-operated animals (n=2, 2 female).
After  reperfusion  and  suturing  the  skin,  each  animal  received  an  injection  of  an
analgesic (tolfenamic acid, 4mg/kg, intramuscularly, Tolfedine 4%, Vétoquinol, Lure,
France) and an antibiotic (cefamandole 15mg/kg, intramuscularly; Kefandol, France, for the
next 3 days). After recovery from anesthesia, the marmosets were returned to their cages and
given access to water and soft food, and then observed for 1 to 2h and daily afterwards.
4.3.2 Photothrombotic cortical lesion (study IV)
Animals were anesthetized with a mixture of Ketasol (100 mg/kg) and Xylasol (0.8 mg/kg) in
0.9  % NaCl.  Anesthetized animals  were  mounted to  a  stereotactic  frame (Stoelting,  Wood
Dale, IL) and the skull was exposed with an approximate 1 cm incision along the midline.
Then the cold light source was placed on the skull over the right sensorimotor cortex (-2.4
mm from bregma).  Before  illumination,  Rose  Bengal  (50  mg/kg,  Sigma,  St.  Louis,  USA) in
saline was given via the tail  vein as a bolus. Subsequently, the cold light (diameter 1 mm)
was switched on for 10 minutes. After the operation, the skin was glued with VetGlue and
the animals were treated for postoperative pain with 10 ml/kg body weight of Rimadyl (0.05
mg/ml, Pfizer Animal Health, The Netherlands) and the local painkiller Xylocain gel (2 %,
AstraZeneca, Södertälje, Sweden).
4.4 BEHAVIORAL TESTS
All  behavioral  tests  were  carried out  in  a  blind manner,  meaning that  the  behavioral  tests
and analysis were conducted by person unaware of the treatment groups.
4.4.1 Tapered/ledged beam walking test (studies I, II and III)
Sensimotor functions of hindlimbs were tested using a tapered/ledged beam walking test
337336. The rats were pretrained on the beam for 3 days before ischemia induction. The animals
were tested before surgery and on post-operative days 14 and 28.
The beam-walking apparatus consisted of a tapered beam with underhanging ledges
on each side to permit foot faults without falling. Rats with ischemic damage are able to use
the ledge as a “crutch” and thus are less prone to learn compensatory postural strategies. The
beam  has  a  starting  point  with  a  platform  at  the  other  end,  and  a  black  goal  box
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(20.5 cm × 25 cm × 25 cm) at the other end. A bright light was placed above the start point to
motivate the rats to traverse the beam.
All trials were videotaped and later analyzed by calculating the slip ratio of the
impaired (contralateral to lesion) forelimb and hindlimb. Steps onto the ledge were scored as
a full slip, and a half slip was given if the limb touched the side of the beam. The used formula
for calculation was; (number of full slips + ½ *half slips/total steps)*100%. The mean of three
trials was used in the statistical analyses.
4.4.2 Cylinder test (studies I, II and III)
The  cylinder  test  was  used  to  assess  spontaneous  forelimb  use  and  imbalance  between
impaired and non-impaired forelimbs 369.  In  the  test,  the  rat  was  placed  in  a  transparent
cylinder (diameter 20 cm) and videotaped during the light part of the light/dark cycle before,
and 14 and 28 days after surgery.
Rats were transported to the videotaping room 20 minutes before the test. After the
habituation phase and tapered/ledged beam walking test, one animal at a time was placed in
the cylinder, and videotaped for 5 minutes. A mirror was placed under the cylinder so that
behavior could be viewed. Exploratory activity for 1–5 min was analyzed in a blind manner
to the treatment groups using a program with slow-motion capabilities.
Forelimb use was observed during the first contact against the wall after rearing and
during lateral exploration of the wall. Independent use of impaired and non-impaired
forelimbs as well as simultaneous use of both forelimbs were calculated. After the start of the
trial, the first forelimb to contact the wall with weight support was scored as an independent
wall placement for that limb. A simultaneous (both forelimbs) movement was scored if the
first limb maintained its position and the other forelimb was placed on the wall. If the animal
placed both forelimbs simultaneously on the wall, that was scored as a simultaneous
movement. To score again, the rat had to remove both forelimbs from the surface of the
cylinder. After the rat removed both forelimbs from the wall, stood with its hindlimbs, and
then contacted the wall with the other forelimb, that was scored as an independent wall
placement  for  that  limb.  When  the  rat  explored  the  wall  laterally,  alternating  both  limbs,
simultaneous movement was scored. If one forelimb was stationary and the other made
several movements, it was scored as one simultaneous movement. Forelimb use during the
ascent and landing was not analyzed 370. Cylinder score for impaired forelimb was calculated
as [contralateral contacts + ½ *bilateral contacts/total contacts]*100%.
4.4.3 Limb placing test (studies I, II and III)
The modified version of the limb-placing test 343 was used to assess hindlimb and forelimb
responses to tactile and proprioceptive stimulation 344,345. The limb-placing test was also used
to assign ischemic animals to equivalent groups on the day after ischemia induction.
The test had seven limb-placing tasks that assess the forelimb and hindlimb responses.
The tasks were scored in the following manner: the rat performed normally, 2 points; the rat
performed with a delay (2 s) and/or incompletely, 1 point; the rat did not perform normally,
0 points. Both sides of the body were tested.
In the first task, the rat was positioned towards the table and its forelimbs were placed
on  the  table.  Each  forelimb  was  gently  pulled  down  and  retrieval  and  placement  were
checked. The second task was the same as the first one except that the rat's head was kept
upward at a 45° angle.  Next,  the rats were placed along the table edge to check for lateral
placement of the forelimb (third task) and the hindlimb (fourth task). In the fifth task, the rat
was again positioned towards the  table  with  the  hindlimbs just  over  the  table  edge.  Each
hindlimb was pulled down and gently stimulated by pushing towards the side of the table.
In the sixth task, the forelimbs of the rat were on the edge of the table and the rat was gently
pushed from behind toward the edge to assess its ability to maintain its grip. In the final,
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seventh task, the rat was suspended 10 cm over a table and the stretching of its forelimbs
towards the table was observed. The rats were habituated for handling and tested before
ischemia induction and then again on postoperative days 2,  3,  4,  5,  7,  10,  14,  19, 21 and 28
(study I); on postoperative days 2, 4, 7, 10, 14, 21 and 28 (study II) or on postoperative days
2, 14 and 28 (study III).
4.4.4 Behavioral tests in mice (study IV)
Beam. This test was performed on day 29. The analysis focused on the total traverse
time, the active time during the test and the number of foot slips.
Cylinder test. The spontaneous activity  of  the  animals  was determined by using the
cylinder test modified for mice 369,371. Therefore, spontaneous movements were videotaped
for 1 minute in a small transparent cylinder (height: 15.5 cm, diameter: 12.7 cm) placed on a
piece  of  glass.  The  number  of  rearings,  forelimb  and  hindlimb  steps,  and  the  time  spent
grooming were measured. The test was performed on day 28 as the first test before the Irwin
test.
Irwin test. To test and survey the general health, each mouse underwent an Irwin test
372. The measured physical characteristics were body weight, body temperature, existence of
whiskers, constitution of the fur and the eyes as well as individual remarks.
The wire suspension test. Neuromuscular abnormalities can be detected with a simple
measure of motor strength. In the wire suspension test, a standard wire cage lid was used.
The test was performed by placing the mouse on top of the lid and gradually turning the lid
upside down. A cut-off time of 60 second was used. The latency to fall down was measured.
4.5 HISTOLOGY
All histological procedures and analyses are also presented in Figure 8.
4.5.1 Perfusion
Animals were perfused transcardically on postoperative day 29 (study I), day 30 (study III)
or day 45 (study V) with 0.9 % NaCl followed by 4 % paraformaldehyde in 0.1 mol/l
phosphate  buffer  (pH  7.4).  The  brains  were  removed  from  the  skulls,  postfixed  and
cryoprotected. Frozen sections (40 μm, study I; 35 μm, study III; 50 μm, study V) were cut
with a sliding microtome and stored in a cryoprotectant tissue collection solution at – 20 °C.
4.5.2 Inflammatory markers (study I)
Glial  fibrillary  acidic  protein  (GFAP)  was  stained  as  a  marker  for  astrocytes  (mouse  anti-
GFAP, Sigma, St. Louis, USA) and OX-42 as a marker of microglia (mouse anti-rat CD11b,
Serotec, Oxford, UK). Then sections were transferred to a solution containing the primary
antibody (GFAP at 1:1,000, OX-42 at 1:4,000) and Tris-buffered saline with 0.5 % Triton X-100
(TBS-T). After incubation in this solution overnight on a shaker table at room temperature
(20 °C) in the dark, the sections were rinsed three times in TBS-T and transferred to a solution
containing the secondary antibody (sheep anti-mouse Ig*biotin; Serotec, Oxford, UK or goat
anti-mouse*biotin; Sigma, St. Louis, USA). After 2 h, the sections were rinsed three times with
TBS-T and transferred to a solution containing mouse ExtrAvidin (Sigma, St.  Louis,  USA),
and then incubated for approximately 3 min with diaminobenzidine (DAB) 92.
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4.5.3 A staining in rats and mice (studies I and IV)
The  accumulation  of  A in  the  thalamus  was  examined  using  a  rodent-specific  primary
antibody (rabbit anti-rodent A3-16, #9151; Covance, USA) and human-specific primary
antibody (mouse monoclonal anti-A, clone W0-2, Millipore, USA). Adjacent sections were
pretreated for 30 minutes with hot (85 °C) citrate buffer. After incubation in citrate buffer, the
sections were rinsed three times with TBS-T (rodent A staining TBS-T pH 7.6 and W0-2 pH
8.6)  and  transferred  to  a  solution  containing  the  primary  antibody  (rodent  specific  A at
1:5,000, human specific at 1:20,000) and Tris buffered saline with TBS-T. After incubation in
this solution overnight on a shaker table at room temperature (20 °C) in the dark, the sections
were  rinsed  three  times  in  TBS-T  and  transferred  to  a  solution  containing  the  secondary
antibody (goat anti-rabbit Ig*biotin 1:500, Chemicon/Millipore USA; goat anti-mouse*biotin
1:500,  Vector,  USA).  After  2  h,  the  sections  were  rinsed  three  times  with  TBS-T  and
transferred  to  a  solution  containing  mouse  ExtrAvidin  (Sigma,  St.  Louis,  USA),  and  then
incubated for approximately 3 min with DAB 92.
4.5.4 Double immunofluorescence staining (study IV)
For assessing the cellular localization of A deposits, a double immunofluorecent staining
for rodent A, neuronal nuclei (NeuN) and GFAP in the thalamus was carried out. Pretreated
sections (see 4.5.3) were incubated overnight with a mixture of primary antibodies (A: rabbit
anti-rodent A3-16, 1:2,000, Covance, USA; NeuN: mouse anti-NeuN, 1:2,000, Millipore,
Temecula,  CA,  USA;  GFAP:  anti-mouse  anti-GFAP,  1:1,000,  Sigma,  St.  Louis,  USA).  After
rinsing  in  TBS-T,  the  sections  were  incubated  with  secondary  antibodies  (A:  Alexa  488-
conjugated  goat  anti-rabbit  IgG,  1:250,  Invitrogen,  Carlsbad,  CA,  USA;  GFAP  and  NeuN:
Alexa 594-conjugated goat anti-mouse IgG, 1:250, Invitrogen, Carlsbad, CA, USA).
4.5.5 A and GFAP stainings in marmosets (study V)
Sections from the four anterioposterior levels (A4, A5.5 for the MD, A8 – for the VPL/VPM
and P3) were used for staining 373. A human-specific antibody (mouse monoclonal anti-hAPP,
6E10, Covance, Emeryville, USA) was used for A staining. Citrate buffer pretreated sections
(30 min, 85 °C) were incubated with the primary antibody (1:1,000) and Tris buffered saline
with 0.5 % TBS-T overnight at room temperature (20 °C). The sections were then rinsed three
times with TBS-T and transferred to a solution containing the secondary antibody (goat anti-
mouse*biotin 1:400; Sigma St. Louis, USA). After 2 h, sections were rinsed and transferred to
a  solution  containing  mouse  ExtrAvidin  (Sigma,  St.  Louis,  USA)  and  then  incubated  for
approximately 3 minutes with DAB 92. Adjacent sections were stained for GFAP (rabbit anti-
GFAP, 1:5,000, Dako, Trappes, France) 329. The used antibody showed A deposits in brain
sections  from  transgenic  Alzheimer’s  disease  mice  and  patients,  which  were  used  as  a
positive staining control.
4.5.6 Calcium staining (studies I, IV and V)
Calcium was stained with the  Alizarin  red method 213. In brief, sections were mounted on
gelatinized glass and immersed in 2 % Alizarin red (w/v, distilled water, pH 4.1 to 4.3; Merck,
Darmstad, Germany) for 30 s followed by rinsing in distilled water. The sections were quickly
dehydrated with acetone and xylene and coverslipped in Depex.
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Figure 8: The histological methods and analysis of the stainings used in this thesis
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4.6 HISTOLOGICAL ANALYSES
4.6.1 Assessment of infarct volumes (studies I, IV and V)
Infarct  volumes  were  measured  in  study  I  by  using  an  image  analysis  system  (MCID,
Imaging Research Inc., Canada) from Nissl-stained sections collected at 0.4 mm intervals. The
image of each section was taken as a 1280x1024 matrix of calibrated pixel units. The digital
image was displayed on a video screen and areas of surviving grey matter in the cortex and
striatum were outlined separately from each hemisphere. The difference between the size of
an  outlined  area  in  the  contralateral  hemisphere  and  the  respective  residual  area  in  the
ipsilateral hemisphere were taken as the infarcted area. The total infarct volume was
calculated by multiplying the infarct area by the distance between the sections and summing
together the volumes for each brain.
Infarct volumes in study IV were measured by using ImageJ from Nissl-stained sections
collected  at  0.175  –  0.245  mm  intervals.  The  mean  area  of  tissue  damage  between  two
sequential sections was multiplied by the distance between the two sections, and these values
were summed up to obtain total infarct volume (mm3).
Lesion volumes in MCAO marmosets were measured from MRI-pictures taken on post-
operative day 7.
4.6.2 Calcium, A, GFAP and OX-42 analysis (studies I and IV)
An  image  analysis  system  (MCID)  and  a  DAGE  MTI  CCD-72  series  camera  were  used  to
quantify activated astrocyte (GFAP) and microglia (OX-42) and A and calcium load in the
thalamus (study I). The digitized image was displayed on a video screen and converted to
gray scale, after which the thalamus was manually outlined and optical densities above the
threshold level taken from the contralateral thalamus were recognized automatically by the
image analysis system. The areal value was taken for statistical analysis.
Images from calcium and A stained sections (study IV) were taken with an Olympus
BX40 microscope and an Olympus digital camera DP50-CU (Japan). From each image, the
thalamus was manually outlined (Photoshop CS3) and the areas of interest were
automatically analyzed by using the ‘magic wand’ tool to outline the specific color of staining
from the background. Measurements were performed from two replicates and the mean
values were used for statistical analysis.
4.6.3 Mapping of A positive cells and calcium in marmoset brains (study V)
6E10-positive cells and calcium positive areas were manually mapped using Stereo
Investigator software (MicroBrightField, Inc., VT, USA). A motorized stage with a microcator
(Heidenhain  EXE  610C)  attachment  (providing  a  0.1  μm  resolution  in  the Z axis)  was
mounted on the microscope. The brain sections were first outlined using a CFI Plan Achro
2× objective (N.A. 0.06, W.D. 7.5). Thereafter, a CFI Plan Achro 10× objective (N.A. 0.45, W.D.
4.5) was used to map cells and areas of interest. The shrinkage of thalamus was assessed from
stained sections by outlining the ipsilateral and contralateral thalamus and calculating the %
change.
4.7 BIOCHEMICAL ANALYSIS
Experimental stroke related changes have been previously demonstrated in biochemical
analyses 99 and thus these kinds of results represent a good supplement to the studies with
only histological and behavioral data. In the present studies (II and III), the changes in A
and calcium levels, as well as in a set of other A and APP processing proteins, were assessed
from thalamic brain lysates.
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4.7.1 Thalamic tissue samples (studies II and III)
Tissue samples from the ipsilateral and contralateral thalamus of MCAO or sham-operated
rats  were  weighed  and  mechanically  homogenized  in  400 l of Dulbecco’s phosphate
buffered saline (DPBS, Lonza, Basel, Switzerland) in an ice bath. Approximately 10-fold
excess of PBS/mg tissue was used.  The tissue homogenates were subdivided into two (study
III) or three fractions (study II) as follows; (study II; 10 % RNA extraction, 45 % total protein
I, 45 % total protein II; study III: 50 % total protein I and 50 % total protein II). For the RNA
extraction, the homogenant was mixed with 500 l of TRIzol® reagent (Invitrogen, Carlsbad,
CA, USA); for total protein I, the homogenant was suspended in DPBS containing EDTA-free
protease and phosphatase inhibitors (1:100; Thermo Scientific, Rockford, IL, USA); and for
total protein II the homogenant was suspended in DPBS without inhibitors. All aliquots were
stored at -70 °C. Total protein I fraction was subjected to Western blotting and A analyses.
Total  protein  II  fraction  was  used  for  measurement  of  calcium  and  -, - and -secretase
enzyme activity.
4.7.2 RNA extraction and qPCR analysis (study II)
Total RNA was extracted from homogenized thalamic tissues using TRIzol® reagent
according to the manufacturer’s instructions. Equal quantities of total RNA samples were
subjected  to  complementary  DNA  (cDNA)  synthesis  using  Superscript  III  reverse
transcriptase (Invitrogen, Carlsbad, CA, USA). Subsequently, SYBR Green Master PCR Mix
(Applied Biosystems, Foster City, CA, USA) and target-specific PCR primers for seladin-1
(5-CAAGCCGTGGTTCTTTAAGC-3 and 5-CATCCAGCCAAAGAGGTAGC-3), TNF-
(5-CGAGTGACAAGCCTGTAGCC-3 and 5-GTGGGTGAGGAGCACGTAGT-3), L-type
calcium channel (LTCC) (5-TTCGATGTGAAGGCACTGAG-3 and 5-
TATGCCCTCCTGGTTGTAGC-3), and glyceraldehyde-3-phosphatase dehydrogenase
(GAPDH) (5-CGTCCCGTAGACAAAATGGT-3 and 5-TCTCAATGGTGGTGAAGACA-3)
were used for amplification of cDNA samples by using a real time quantitative PCR machine
(7500 Fast Real Time PCR System, Applied Biosystems, Foster City, CA, USA). PCR primers
were designed to amplify a region extending across at least two different exons. A standard
curve method was used to obtain seladin-1, TNF-, LTCC, and GAPDH levels. The mRNA
levels of each gene were normalized to those of GAPDH from the same samples.
4.7.3 Western blotting (study II)
Total proteins were extracted by using TPER protein extraction buffer (Pierce/Thermo
Scientific, Rockford, lL, USA) containing protease and phosphatase inhibitors
(Pierce/Thermo Scientific, Rockford, lL, USA) from an aliquot of total protein I fraction. After
protein quantification with the bicinchoninic acid (BCA) assay (Pierce/Thermo Scientific,
Rockford, lL, USA), the proteins (30–50 μg/lane) were separated by 4–12% Bis-Tris-
polyacrylamide gel electrophoresis (PAGE; Invitrogen) and blotted onto Immun-Blot
polyvinylidene fluoride membranes (Bio-Rad, Hercules, CA, USA). Primary antibodies
against  APP  C-terminus  (A8717,  Sigma-Aldrich,  Saint  Louis,  MO,  USA),  GGA3  (BD
Biosciences, Dako, Glostrup, Denmark), GFAP (BD Biosciences, Dako, Glostrup, Denmark),
GAPDH (ab8245, Abcam, Cambridge, MA, USA), IDE (ab32216; Abcam, Cambridge, MA,
USA),  neprilysin  (NEP,  AF1126;  R&D  Systems,  Minneapolis,  MN,  USA)  and  low-density
lipoprotein receptor-related protein (LRP, ab92544; Abcam, Cambridge, MA, USA) were
used for immunoblotting. After incubation with appropriate secondary horseradish
peroxidase-conjugated antibodies (GE Healthcare, Piscataway, NJ, USA), the membranes
were exposed to a chemiluminescent substrate (ECL™ Advance Western Blotting Detection
Kit, Amersham Biosciences/ GE Healthcare, Piscataway, NJ, USA), and protein bands were
detected with ImageQuant RT ECL Imager (GE Healthcare, Piscataway, NJ, USA). Western
blot images were quantified using Quantity One software (Bio-Rad, Hercules, CA, USA). SH-
SY5Y human neuroblastoma cells over-expressing APP751 isoform were used as a control for
size comparison of the bands 374.
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4.7.4 A and soluble APP and A measurements (studies II and III)
Soluble or insoluble A x-40 and A x-42 (A40 and A42) levels were measured from the total
protein I fraction. Protein aliquots were first ultracentrifuged (100,000 x g, 50.4 Ti rotor;
Beckman Coulter, Palo Alto, CA, USA) for two hours at 4 °C, and the supernatant (= soluble
fraction)  was  collected.  Subsequently,  the  remaining pellet  was  resuspended in  guanidine
buffer  (5  M  guanidine-HCl  /  50  mM  Tris-HCl,  pH  8.0),  incubated  for  2  hours  at  room
temperature on a shaker, and diluted 1:50 in BSAT-DPBS (5% BSA/0.03% Tween-20 in DPBS,
pH 9.0) containing protease and phosphatase inhibitors. Finally, the suspension was
centrifuged  for  20  minutes  at  15700  x  g  and  the  supernatant  (=  insoluble  fraction)  was
collected  for  A measurements.  Both  insoluble  and  soluble  A40 and  A42 levels were
determined using monoclonal and HRP-conjugated antibody-based Human/Rat A 40 (294-
62501) and Human/Rat A 42 (High-Sensitive; 290-62601) ELISA Kit (Wako, Osaka, Japan).
After 30-minute incubation at room temperature, the reaction was terminated and the
absorbance was measured at 450 nm with an ELISA microplate reader (Wallac/Perkin Elmer,
Waltham, MA, USA). A concentrations were expressed per tissue weight, and in study III
per amount of soluble total protein. Soluble sAPP and sAPP total (= sAPP + sAPP) levels
were detected from the same protein fraction as soluble A using Western blot analysis with
6E10 (Signet Laboratories, Dedham, MA, USA)) and 22C11 (Mab348, Millipore, Darmstadt,
Germany)) antibodies, respectively.
4.7.5 Calcium measurements (studies II and III)
Tissue homogenate samples (20 μl) were digested (CEM MDS-2000 microwave digestor) in
100 μl suprapure nitric acid (Merck, Merck, Whitehouse Station, NJ, USA). After digestion,
100 μl 2% lanthanum solution (Riedel de Haen, Honeywell Riedel-deHaën, Hanover,
Germany) was added and the samples were diluted to a volume of 1 ml with Milli-Q water.
Calcium measurements were carried out with a ZEEnit 700 atomic absorption spectrometer
(Analytik Jena AG, Jena, Germany) with a calcium hollow cathode lamp at wavelength of
422.7 nm using an air-acetylene flame and SFS6 injection module. Calcium concentrations
were expressed per tissue weight.
4.8 STATISTICAL ANALYSIS
All  statistical  analyses  were  performed  with  SPSS  software.  The  non-parametric  Mann-
Whitney U-test (equal variances not assumed) was used for statistical analysis of limb placing
test. Beam walk and cylinder test were analyzed using repeated measures analysis of
variance (ANOVA). Then comparisons between groups were made using one-way ANOVA
followed by a post hoc test (LSD). The effects of genotype and treatment on infarct volumes,
A and calcium staining were analyzed using two-way ANOVA followed by Student t-test,
if needed. Differences in the infarct volumes, calcium staining and immunohistochemistry
between  vehicle  controls  and  drug  treated  rats  and  mice  were  analyzed  using  one-way
ANOVA followed by LSD. Non-parametric Mann-Whitney U-test (equal variances not
assumed) and one-way ANOVA with a post-hoc test (LSD) was used for statistical analysis
of biochemical data. Correlations were determined using Pearson’s correlation coefficient.
GraphPad Prism5 software was used to finalize the figures.
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5 Results
5.1 STUDY I
5.1.1 Experimental groups
From forty animals 10, were sham-operated. One of these died during the follow-up. From
the thirty MCAO-operated animals,  seven died <48 hours after the surgery and three died
during the follow-up. One animal was excluded from the study since its limb placing test
score  was  10  or  higher.  Thus,  the  experimental  groups  were:  sham+vehicle  (n=4),
sham+ibuprofen (40 mg/kg; n=5), MCAO+vehicle (n=11) and MCAO+ ibuprofen (40 mg/kg;
n=8). Sham-operated animals did not differ in their behavioral or histological results and thus
were pooled into one group.
During the course of the study, the animals were observed daily and their weight was
monitored. MCAO rats lost weight (20%) during the first postoperative days. In addition, at
later time points, ibuprofen treatment seemed to decrease body weight in both sham-
operated and in MCAO rats (4-8%) as compared to vehicle-treated rats.
5.1.2 Ibuprofen treatment does not change infarct volume nor mitigate inflammation
The  infarct  size  in  the  cortex  and  striatum  was  measured  from  Nissl-stained  sections  in
MCAO  rats  after  the  28-day  follow-up.  There  was  no  significant  difference  in  infarct  size
between vehicle and ibuprofen-treated rats. Note that the thalamus was spared from acute
ischemic damage because of its blood supply through the posterior cerebral artery.
Activation of astrocytes and microglia in the thalamus was measured from GFAP and
OX-42-stained sections, respectively. A robust increase in both GFAP and OX-42 (Figure 9)
staining  was  observed  in  the  ipsilateral  thalamus  and  in  the  areas  adjacent  to  the  infarct.
Ibuprofen treatment increased OX-42 staining (P<0.05) as compared to vehicle treatment.
Rodent  specific  A antibody  was  used  to  reveal  the  A deposits  in  the  thalamus.
Calcium accumulation was measured from Alizarin red -stained sections. Both A and
calcium stainings were observed only in the thalamus of MCAO rats (Figure 9). With both
stainings, statistical differences were observed only between sham-operated animals and
MCAO animals. Ibuprofen treatment did not alter the extent of accumulation of A or
calcium in the thalamus.
5.1.3 Behavioral tests revealed no differences between the groups
All behavioral tests indicated that the MCAO rats were severely impaired shortly after the
operation. A partial recovery was evident in all the behavioral tests, particularly in the limb
placing test. Ibuprofen treatment did not have any significant effect on hindlimb function as
measured in the tapered/ledged beam or in the cylinder test, which measures spontaneous
forelimb use. The significant overall group effect was attributable to the difference between
sham-operated and MCAO rats during the follow-up.
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5.2 STUDY II
5.2.1 Experimental groups
Eight out of a total of 31 animals were sham-operated. Two of sham-operated animals died
during the follow-up due to unsuccessful per os administration. Twenty-three animals went
through the MCAO-operation; of these 8 died within 48 h of surgery. One animal died during
the follow-up. A total of two animals were excluded from the study because they had a limb
placing  test  score  10  or  higher.  Thus  the  experimental  groups  were:  sham+vehicle  (n=6),
MCAO+vehicle (n=7) and MCAO+bepridil (50 mg/kg; n=5). Bepridil treatment did not
influence the body weight during the follow-up.
Figure 9: GFAP, OX-42, calcium and A staining 29 days after MCAO in rats. The area of staining
in  the  thalamus  was  measured  by  image  analysis  software (MCID; values are mean±SEM;
**p<0.01; ***p<0.001). Robust GFAP and OX-42 stainings in the ipsilateral thalamus and
cortex  adjacent  to  the  infarct  area  were  observed  in  MCAO  rats.  Ibuprofen  treatment  (40
mg/kg/day) effect was seen in the OX-42 microglia staining between MCAO groups. Calcium and
A stainings were observed in the same areas in the ipsilateral thalamus in both MCAO groups.
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5.2.2 Calcium, A40 and A42 levels decline in the ipsilateral thalamus after bepridil
treatment
After the 29-day follow-up, the thalamus samples were analyzed for levels of calcium, A40
and A42. Bepridil treatment decreased the measured levels as compared to vehicle treated
animals (Figure 10). Correlation analyses revealed a positive correlation between the levels
of A42 and calcium (r=0-85, P<0.01) and between A40 and calcium (r=0.74, P<0.01; data not
shown) in the ipsilateral thalamus.
5.2.3 Bepridil treatment does not influence the APP cleavage enzymes
Consistent with the previous studies 9,  the  levels  of  CTF  were  increased  in  the  ipsilateral
thalamus after MCAO (~1.4-fold). In addition, the levels of total APP were significantly
decreased in the ipsilateral thalamus. Bepridil treatment did not change the GGA3 levels as
compared to vehicle-treated animals, explaining also the increase (~1.8-fold) of BACE-
activity in the ipsilateral thalamus in both MCAO groups. The activity of - and -secretases
did not differ between the MCAO groups. Sham-operated animals did not display any
alterations in the GGA3 or BACE levels.
5.2.4 Bepridil treatment has no effect on levels of IDE, NEP, LRP, LTCC or on the
inflammation response
In agreement with previous findings 9,  IDE  levels  were  significantly  increased  in  the
ipsilateral  thalamus  in  both  MCAO  groups,  whereas  NEP  and  LRP  levels  remained
unchanged in MCAO- and sham-operated animals. LTCC levels were significantly decreased
after MCAO, without any differences between vehicle- and bepridil-treated MCAO animals.
The levels of two inflammation markers, GFAP and TNF-, were increased in the ipsilateral
thalamus in both MCAO groups.
5.2.5 Bepridil restores seladin-1 mRNA and protein levels
Previous  studies  have  shown  that  the  mRNA  levels  of  seladin-1,  which  in  the  normal
situation protects cells from A toxicity and oxidative stress, are down-regulated in brain
regions vulnerable to AD 375,376. Quantitative PCR analysis revealed a significant 30-40%
decrease in GAPDH-normalized seladin-1 mRNA and protein levels in the ipsilateral
thalamus after MCAO in rats treated with vehicle. In contrast, a similar change was not
observed in the bepridil-treated MCAO rats.
Figure 10: A) Calcium levels in the thalamus after 29-day follow-up. B) A40 and (C) A42 levels
in the thalamus after 29-day follow-up. There was a statistical difference between bepridil- and
vehicle-treated MCAO rats. Statistical analysis revealed a significant difference between bepridil-
and vehicle-treated MCAO rats in the ipsilateral thalamus. Values are mean±SEM, *P<0.05.
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5.2.6 Bepridil treatment improves the behavioral recovery of MCAO rats in the cylinder
test
Behavioral measurements detected the presence of a severe motor deficit initially after
MCAO operation, which was followed by a partial recovery. The significant group effect in
all behavioral test was explained by the difference between sham-operated and MCAO-
operated animals. Limb placing test or beam walking test did not show any statistical
differences between the treatment groups. Spontaneous forelimb use, as measured by the
cylinder test, revealed a statistical improvement in favor of bepridil treatment on post-
operative day 28.
5.3 STUDY III
5.3.1 Experimental groups
In study III, the occlusion time was 90 minutes instead of the 120 minutes used in studies I
and II. Twelve animals had to be excluded from the study since they had a score 10 or more
in the limb placing test. Three animals died >48 h after the surgery and three animals died
during the follow-up period. Weight loss was observed in the KB-R7943-treated MCAO rats.
5.3.2 Calcium, A40 or A42 levels in the thalamus does not differ between KB-R7943
and vehicle treated MCAO animals
Statistical analysis of calcium and A in the thalamus did not reveal differences between the
treatment groups.  The mean ipsilateral thalamic levels for calcium was 24 ug/ul/g and for
A40 35 pmol/l/μg and for A42 3.3 pmol/l/μg in the KB-R9743 treated rats and 20.6 ug/ul/g /
38.7 pmol/l/μg / 3.7 pmol/l/μg in the vehicle-treated groups (Figure 11).
5.3.3 Behavioral tests do not reveal any beneficial effect after KB-R7943 treatment
The limb placing test was used to analyze the sensorimotor, tapered/ledged beam for
hindlimb, and cylinder for forelimb deficits. None of these behavioral tests detected any
differences  between  the  MCAO  groups.  An  overall  group  effect  was  explained  by  the
difference between sham-operated and MCAO animals.
Figure 11: Analysis of (A) calcium, (B) A40 and (C) A42 in  the  thalamus  after  the  28-day
follow-up. Statistical analysis did not detect any difference between MCAO groups. Values are
mean±SEM.
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5.4 STUDY IV
5.4.1 Experimental groups
In  study  IV,  the  total  of  63  animals  were  used;  33  transgenic  mice  and  30  non-transgenic
wildtype  mice.  The  animals  killed  during  the  operations  were  euthanized  due  to  an
unsuccessful intravenous injection. Six animals died during the follow-up and a total of six
animals had to be excluded from the study since they did not have any lesions according to
the histological analysis. The groups were: Tg (transgenic)+bepridil 50 mg/kg (n=10),
Tg+vehicle (n=12), nTg (non-transgenic)+bepridil 50 mg/kg (n=13) and nTg+vehicle (n=10).
The  cortical  ischemic  model  caused  an  approximately  1  mm3 lesion.  A  small  but  not
statistically significant increase in the infarct volume was detected in the non-transgenic
bepridil-treated animals after the 29-day follow-up.
From four to five months old hAPPSL transgenic and non-transgenic animals were used
in this study. Already at the beginning of the study, wildtype mice were heavier than their
transgenic littermates. The photothrombotic cortical lesion model caused a slight increase in
the body weight shortly after the operation.
5.4.2 Behavioral tests do not reveal any differences between the groups
Behavioral tests for mice did not show statistical differences between the groups one month
after  the  operation.  Only  in  the  beam  test  was  there  a  trend  that  non-transgenic  animals
treated with bepridil made fewer slips in the most demanding beam (round and diameter 0.5
cm). The 60 s wire test or cylinder test did not reveal any differences between the groups.
5.4.3 Rodent A and calcium accumulation decreases in bepridil-treated non-transgenic
mice, but not in hAPPSL mice
A rodent specific A antibody was used to reveal endogenous A deposits in the thalamus
after cortical photothrombosis. The genotype had a significant effect on A load in the
thalamus (P<0.01) and the accumulation of A was more pronounced in non-transgenic
animals (P<0.01) (Figure 12A).
A significant treatment-effect was seen in the Alizarin red –stained sections (P<0.01).
However, there was no treatment and genotype interaction, indicating that bepridil-
treatment affected similarly the transgenic hAPPSL and wildtype mice (Figure 12B).
5.4.4 A deposits are extracellular when examined 30 days after the cortical lesion
Double  immunofluorescence  staining  for  rodent  A,  neuronal  nuclei  (NeuN)  and  GFAP
showed that A-positive deposits were not localized in neurons or in astrocytes, evidence
that A deposits are extracellular for at least the first 30 days after the cortical lesion.
42
5.5 STUDY V
5.5.1 Experimental groups
In study V, six common marmosets (three males and three females) were used, from which
four (3 males, 1 female) were subjected to MCAO and two (2 females) to the sham-operation.
During  the  surgical  procedure,  arterial  blood  pressure,  heart  rate  and  body  temperature
remained stable within physiological ranges (mean arterial blood pressure: 67±6 mmHg;
heart rate: 198±2 min-1; temperature 37.1±0.1 °C). Thalamus atrophy was seen in all the
animals  in  the  histological  analysis  (-21.8  ±7.4  %,  mean  ±  SEM)  but  MRI  imaging  did  not
reveal any signs of neuronal degeneration in the thalamus at seven days after the MCAO. In
addition, a hyperintense signal was found in substantia nigra in all of the animals with
subcortical infarcts.
The histological analysis demonstrated patchy areas of calcium and A-positive
neurons in the ipsilateral cortex next to the infarct area. In one animal, calcium staining was
observed also in the contralateral hemisphere (#9142). Remote regions like substantia nigra
and hippocampus were occasionally stained for calcium. Sham-operated animals did not
exhibit any calcium or A-positive staining. On the contrary, GFAP immunostaining
displayed a marked increase in the astroglial marker in the ipsilateral cortex and thalamus
(see Figure 13).
Figure 12: Representative images from rodent A (upper panel) and Alizarin red –stained (lower
panel) sections 30 days after photothrombotic cortical lesion. A) Quantitative  analysis  of  A
staining. B) Quantitative analysis of Alizarin red –staining. Values are mean±SEM.
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Figure 13: Representative illustration of pathological changes in marmoset brains 7 days (MRI
images) and 45 days (immunohistochemical stainings) after MCAO. Grey areas in the schematic
brain pictures on the left side images display the ischemic area corresponding to the MRI image
from the same coronal level in the right column. Red areas represent the stainings for calcium,
and the green areas are for  A.  High magnifications images from patchy groups of  A-positive
neurons (A) and calcium deposits (B) in the peri-infarct regions in the marmoset subjected to
MCAO  (#9142).  Staining  for  glial  fibrillary  acid  protein  (GFAP) showed  a  greater  extent  of
astrogliosis in the ipsilateral cortex (C) and thalamus (D) after MCAO.
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6 Discussion
Stroke is one of the leading causes of death and disability worldwide 2,377. Thrombolytic
therapy is currently the only available drug treatment in the acute phases of stroke; its mode
of  action  is  to  restore  the  blood  flow  to  the  ischemic  brain  before  there  is  any  permanent
damage. However, thrombolytic therapy is only available for a small proportion of stroke
patients due to the narrow therapeutic time window, contraindications to therapy, and
limited access for the individuals living in remote regions (see 33,378). An alternative strategy
is to target secondary damage which would have a wider therapeutic time window.
The secondary pathology in stroke resembles in several respects that are seen in the AD
92,282,285,291,  making it  an interesting phenomenon for  use  as  a  stepping stone towards novel
drug  discoveries.  There  is  ample  evidence  that  ischemic  stroke  may  contribute  to  the
pathogenesis of AD. First, there is epidemiological studies indicating that risk factors for
stroke are associated with AD 45.  Second,  60-90  %  of  AD  patients  exhibit  cerebrovascular
pathology at autopsy, and the coexistence of stroke and AD occurs more than can be
accounted by chance alone 46 Third, stroke intensifies the presence and severity of the clinical
symptoms of AD and increases AD pathology in the brain 47,48. The following discussion starts
with the methological issues, since these have to be taken into considerations in all stroke
experiments. Most importantly, an attempt is made to find reasons why translation of stroke
therapies from in vitro and in vivo studies to clinical trials has been so challenging 38. The
second part of discussion delves more into the results achieved from the five studies included
in the thesis.
6.1 METHOLOGICAL CONSIDERATIONS
International recommendation such as STEPS (Stem Cell Therapies as an Emerging Paradigm
in Stroke; 379)  and  STAIR  (Stroke  Therapy  Academic  Industry  Roundtable; 294) provide
guidelines and recommendations to improve the quality of research, which are also relevant
to the studies conducted in this thesis.
When one assesses the possible pitfalls in the preclinical studies,  the first point to be
considered is anesthesia. It is well known that many anesthetic gases, like halothane used
here, are neuroprotective 380. It is important to note that halothane has also been shown to
inhibit the activity of NCX 381. Lidocaine and buprenorphine, which are used for
postoperative care, have also putative neuroprotective properties. Taken together, this
possible “second” treatment may counteract acute neuronal loss. However, it is unlikely that
the anesthesia used during the operation would have any effect on delayed secondary
pathology occurring after cerebral ischemia.
A relevant issue in drug research and in vivo testing is valid drug dose. In the present
studies, maximal drug doses were selected based on values in the literature. The reasons why
it  was  decided  not  to  undertake  a  proper  dose-response  evaluation  were  the  preliminary
nature of the studies and complicated and laborious study design with additional
experimental groups. Similar to dose, the route of dosing will need to be investigated more
carefully in the future studies.
The time window for drug treatment is one of the major questions in preclinical stroke
research.  In  the  present  studies  the  drug administration was started on postoperative  day
two since it was decided to avoid interference with the maturation of ischemic damage.
Whether a more delayed start of treatment would have been more effective in targeting
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secondary pathology, remains to be determined. As mentioned in the  STAIR guidelines 294,
also co-morbidities should be studied in greater detail, i.e., examining old animals with pre-
existing  hypertension, diabetes and hyperlipidemia (see 382) or daily treatment with non-
steroidal anti-inflammatory drugs (NSAIDs) 383.  For  example,  aged  neurons  are  likely  to
display enhanced release of Ca2+ from the ER 384,385, diminished Ca2+ extrusion through the
plasma membrane ATPase 386, reduced cellular Ca2+ buffering capacity due to impairment of
the SERCA pumps 387, and a diminished mitochondrial Ca2+ sink capability 388,389. It remains
to be seen whether industry and academia would be willing to fund these complex studies
mimicking real life scenarios after so many failures in the past.
The white and gray matter proportion difference between species may be one of the
most  important  issues  preventing  preclinical  data  transfer  to  clinical  practice.  As  seen  in
Table 1,  the ratio between the grey and white matter differs from 12:1 (in mice) to 1.5:1 in
humans, clearly emphasizing the evident physiological difference. This difference has been
seen also in preclinical studies, where relatively a large lesion in rodent brain causes
significantly smaller deficits in functionality as compared to humans. On the other hand,
atrophy of the brain is an important biomarker for AD 390; it seems that the early changes
prior to the symptomatic onset of disease occurs in the white matter, which eventually lead
to the pathological changes in the grey matter 391. In addition to physiological differences
between species, neuroprotective therapies that are effective in the gray matter do not
necessary work in the white matter. MK-801 is good example of this phenomenon i.e., it was
claimed to be neuroprotective against selective neuronal necrosis 392,393, but it was not able to
attenuate white matter damage in cats 394. However, the AMPA antagonist, SDB502, has been
shown to reduce both grey and white matter damage in cats 395. Indeed, blockade of sodium
channels, calcium or AMPA receptors has been hypothesized to be important for white
matter protection (see 396,397) which could mean that targeting the similar channels in pre- and
postsynaptic areas might eventually lead to a better secondary damage protection and
recovery.  A  recent  study  with  mice  has  also  shown  that  a  white  matter  injury  differs
depending on the age of the animal, e.g., a white matter injury in older mice is more related
to glutamate activated AMPA/kainate receptors rather than to removal of calcium or
inhibition of NCXs 398.
Functional behavioral tests have been developed to assess neurological outcome
following stroke in rats, but there has been only modest success in determining a correlation
between the size of ischemic injury and the extend of the behavioral impairment 340,369,399,400.
This may be partly related to the rapid spontaneous recovery of rodents or to the
compensatory strategies that they develop. The battery of behavioral tests selected in the
present  studies  are  relatively  easy  for  rats  to  perform.  More  demanding  behavioral  tests
might have revealed differences between treatment groups, but on the other hand, the
number of tests would have been lower due to time and personnel related issues. At the same
time it has to be remembered, that all the extra handling and change in the environment may
stress the animals and thus may worsen the behavioral outcome. Cognitive abnormalities are
also common after ischemic brain injury 153,333, but these were not studied in this project.
It is noteworthy that ischemic brain injury does not result in long-lasting neurological
deficits in ischemic animals 153,333, meaning that ischemic animals eventually seem to function
normally in the behavioral tests, even though the ischemic lesion is still evident in the brain.
After an ischemic brain injury in gerbils, impaired behavior lasted up to 6 months as revealed
by longer exploration time in open-field test 401,402. However, it must be acknowledged that
any treatment-induced behavioral improvement may be due to enhanced compensatory
learning (see 357,403). To illustrate this possibility in a stroke-like behavior, if one hindlimb of a
neurologically intact animal is peripherally incapacitated, tapered/ledged beam and
treadmill walking and rotarod performance are compromised severely at first but gradually
improve because the animal may learn new ways to rely on the other limbs or to use a tail-
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based strategy for balance and movement 404. Analysis of high speed video recording frame-
by-frame is a powerful tool with which to differentiate true recovery and compensation.
One  of  the  most  important  issues  is  blind  assessment  of  all  behavioral  studies  and
randomization. In the present studies, the persons who tested the animals and later analyzed
video recording were unaware of the treatment. Thus, one can be sure that these data were
not biased in this respect. Allocation of animals to different experimental groups
(randomization), may also bias the data. It was decided to assess the behavioral impairment
after the operation, in order to exclude those rats with incomplete lesion and then the rest of
the animals were allocated to behaviorally equal groups. The criteria for inclusion/exclusion
were determined before the study.
Another aspect as important as the blind assessment and randomization, is to conduct
power calculations prior to the studies. This is a mathematical method used to evaluate the
number of animals needed in the study to achieve statistical differences in behavioral
analysis.
6.2 INFLAMMATION IN STROKE AND AD
Proinflammatory pathways are triggered both in stroke 58,60,405,406 and AD 407,408. In addition, it
has  long  been  known  that  individuals  who  have  suffered  severe  or  chronic  periods  of
hypoxia  are  more  likely  to  develop  AD  later  in  life 409.  Up-regulation  of  APP  mRNA  and
protein after ischemia has been shown in various studies 14,410,411 to lead consequently to an
increase in A levels. Interestingly, many of the cell functions related to A production seem
to involve calcium signalling. Previous studies have shown that ibuprofen treatment
decreases  the  formation  of  A plaques  in  transgenic  AD  mice  and  improves  functional
outcome in association with a reduction of inflammatory mediators 412–418. However, the
preclinical studies have not been unambiguous 419. For example, Morihara and co-workers
have proposed that ibuprofen may interact via interleukin pathways rather than via
impairing the production of A to prevent AD in mice models 420.  In ischemia studies,  the
putative pathways/targets are ibuprofen suppression of NMDAR induced cell death 421,
reduced striatal damage via suppression of ICAM-1 422, and/or cyclooxygenase inhibition
during reperfusion 423. In addition, systemic inflammation may be one of the common causes
leading to a worse outcome in stroke 118,119 and  to  accelerating  the  onset  of  AD 120,121. The
importance  of  BBB  breakdown  in  both  diseases  is  evident,  the  main  difference  is  in  the
robustness of blood-derived cells penetrating into the brain 123,124,136. Logically, one could
speculate that this knowledge forms the basis for the hypothesis of using NSAIDs as an acute
treatment for stroke and as a preventive treatment for AD. However, randomized clinical
trials  summarized  in  a  large  meta-analysis  have  not  proven  the  preventive  hypothesis  of
these drugs in AD 424. In addition, the chronic use of NSAIDs in clinical trials has been claimed
to increase the risk of stroke 425.
In the present study, it was decided to evaluate the anti-inflammatory hypothesis in
MCAO rats with ibuprofen treatment starting on day two after ischemia and to follow the
functional recovery with a battery of behavioral tests.
Ibuprofen treatment (40 mg/kg/day, per os) did not exert any beneficial effects during
the 28-day follow-up. The ibuprofen-treated animals lost more weight during the first days
of recovery after stroke than the vehicle-treated animals. However, the behavioral tests did
not reveal any differences between the treatment groups. Histological staining for astrocytes
in the ipsilateral thalamus did not detect difference between the MCAO groups. Instead,
microglia staining did exhibit an increase in the ipsilateral thalamus of the ibuprofen-treated
animals, which is quite opposite to the original hypothesis.
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In conclusion, ibuprofen treatment did not prevent or modify secondary thalamic
changes  in  the  thalamus.  This  may  have  been  because  the  dose  was  too  low  or  due  to
inadequate transportation into the thalamus through the BBB. However, the delayed
recovery (slow weight gain) indicates that with per os administration this is the maximum
dose of ibuprofen which can be given in chronic administration. It seems that the underlying
mechanisms  of  secondary  pathology  in  the  thalamus  in  stroke  cannot  be  reversed  by
treatment with a non-steroidal anti-inflammatory drug.
6.3 CALCIUM CHANNELS AS A TARGET FOR STROKE AND AD
The influence of calcium dysregulation on the metabolism and production of A has not been
thoroughly studied as the role of A in calcium signaling. Nevertheless, recent studies have
revealed changes in calcium levels and dynamics sufficient to alter the metabolism and
production of A, leading to the proposal that of calcium may be one of the causative factors
in late-onset AD 426.
During the past decade drug discovery for AD has focused on inhibitors of -secretase
and BACE responsible for the cleavage of A peptide from APP 427–429. Studies with positive
behavioral outcomes have been conducted with anti-BACE treatment in transgenic model of
A pathology,  even  though  that  the  burden  of  A in  the  brain  did  not  change 430. This
indicates that other cascades, rather than the formation of A plaques, have a major impact
on  the  development  of  the  disease.  One  suggestion  is  that  there  is  a  pre-existing  calcium
dysfunction in the brain. This raises the possibility of determining whether prevention of
calcium accumulation by treatment with calcium channel blocking drugs could also decrease
the A burden.
The  major  sources  of  intracellular  Ca2+ are  influx  through  NMDARs  or  VDCC  and
release of Ca2+ from intracellular Ca2+ stores. Calcium channel inhibitors have been designed
to target VDCC and thus prevent intracellular calcium overload. Earlier studies have shown
that A causes an increase in the intracellular calcium content via VDCC and calpain related
functions 282, which in turn leads to further increases in A production. Epidemiological
studies have revealed that calcium channel inhibitors prevent 431 or slow the rate of
progression of AD 432,433.
Bepridil is a diarylaminopropylamine derivate having both antianginal and
antiarrhythmic effects 434. It has multiple inhibitory effects on ionic currents, including the L-
type 435 and T-type  Ca2+ currents 436, as well as on K+ channels 437–440 and Na+ channels 441. In
addition, bepridil is known to inhibit BACE mediated cleavage of APP both in vitro and in
vivo by  increasing  the  pH  in  the  endosomal  compartments 442. Furthermore, bepridil
modulates -secretase-mediated APP cleavage independently of endosomal alkalization.
Previous  studies  have  shown  that  NCX,  operating  in  the  forward  mode,  is  more
strongly inhibited by bepridil  rather than in the reverse manner of action 443,444. The site of
action of bepridil may be located on the cytoplasmic side of the exchanger 434, thus raising the
question of whether other calcium channel inhibitors would be more effective against the
NCX  by  targeting  the  extracellular  compartments  of  the  exchanger.  In in vitro studies,
bepridil  has  been  shown  also  to  bind  to  albumin 434,  thus  decreasing  the  amount  of  free
bepridil available to cross the BBB. Another protein compromising the free amount of
bepridil is alpha-1-acid glycoprotein, which has high affinity for bepridil 445,446. These
previous results together with the hypothesis that calcium may be the primary trigger for
caspase-3 mediated GGA3 cleavage leading to overexpression of BACE and thus increase of
A production 9,275,276 are the reasons why it was decided to test whether bepridil treatment
could prevent calcium and APP/A dysfunction in the thalamus after experimental ischemia.
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Studies II and IV evaluated the effects of treatment with a non-selective calcium channel
inhibitor, bepridil, after experimental focal ischemia in rats and in AD transgenic mice. The
ischemic methods selected are described in more detail described in the materials and
methods. The main difference between studies being the intra-arterial filament model was
used in rats, whereas photothrombotic occlusion was used in mice.
In  study  II  the  transient  filament  model  induced  a  large  cortical  infarction  in  the
ipsilateral hemisphere and caused a severe initial sensorimotor impairment. Bepridil (50
mg/kg/day, per os)  treatment  decreased  calcium  and  soluble  A40 and  A42 levels  in  the
ipsilateral thalamus of MCAO rats when it was assessed at the 29-day follow-up. In Pearson
correlation analysis, calcium levels strongly correlated with the soluble A42 levels evidence
for  an  association  between  these  two  factors.  In  addition,  there  was  also  a  significant
improvement in the rat’s performance in the forelimb function measuring cylinder test in the
bepridil-treated  MCAO  rats  28  days  after  the  ischemic  onset  as  compared  to  the  vehicle
treated MCAO rats. However, bepridil treatment did not change the expression of the
inflammation  markers  (GFAP  and  TNF-)  in  the  ipsilateral  thalamus  in  the  western  blot
analysis. In addition, expressions of IDE, NEP and LRP did not differ between the bepridil
and vehicle treated MCAO, suggesting that some other factor(s) must play a more important
role in A clearance after stroke.
Bepridil treatment (50 mg/kg/day, per os)  in  study IV was started two days  after  the
photothrombotic cortical lesion. At the follow-up assessment, bepridil treatment seemed to
have  increased  infarct  volumes  in  the  transgenic  AD  animals,  but  not  in  the  wildtype
littermates. Increases in infarct volumes have been observed in previous transgenic AD-mice
studies, when compared with wildtype mice 204,447,448, supporting the concept of increased
susceptibility to ischemia as a result of neurotoxic effects of A in the post-ischemic brain.
On the contrast, in this present study the presence of the transgene did not effect the infarct
size in vehicle treated animals. One possible explanation is the fact that quite young animals
(4-5 months) were used at a timepoint, at which the early signs of A plaque formation have
been seen 449,450. In addition, A and calcium analyses were performed in the thalamic areas,
and  it  was  observed  that  cortical  lesion  increased  A and  calcium  burden  in  the  non-
transgenic animals, but not as much as in the transgenic animals. Indeed, bepridil treatment
seemed to decrease the A burden in the non-transgenic animals, but no effect was seen in
the transgenic AD animals. Statistical analysis revealed that bepridil treatment decreased the
calcium burden in both genotypes.
The behavioral tests in study IV did not detect statistical differences between the
groups. This might be due to the two different neurological disorders, which should be tested
so that common symptomatic impairments in both diseases could be distinguished, e.g.,
cognitive tests that would to measure AD symptoms and sensorimotor tests that would
assess  stroke-related impairment.  The small  size  of  mice  will  make it  necessary that  more
sophisticated behavioral tests are used to avoid any possible compensatory movements.
Based  on  the  histological  results,  one  might  say  that  in  the  early  phase  of  AD
development, the underlying APP/A cascades may even be protective against cortical
stroke.
6.4 A REVERSE SODIUM/CALCIUM CHANNEL INHIBITOR DOES NOT
HINDER SECONDARY DAMAGE AFTER STROKE
Similar to bepridil (used in studies II and III), originally KB-R7943 [2-[2-[4-(4-
nitrobenzyloxy)phenyl]-ethyl]isothiourea methanesulfonate] was developed for treatment of
cardiac arrest, a condition where calcium overload triggers arrhythmias in the heart muscle.
Recent reports have shown that KB-R7943 exerts an inhibitory effect on several other ionic
50
transport  mechanisms,  such  as  L-type  VDCC.  Moreover,  KB-R7943  has  been  reported  to
inhibit NMDAR 270,  a  process  already  described  important  in  ensuring  intracellular  Ca2+
homeostasis 223. In addition, KB-R7943 can inhibit the reverse mode of NCX more potently
than the forward mode 451,452. Interestingly, KB-R7943 seems to have a different mechanism
of action to block NCX activity depending on the gene product involved; NCX3 inhibition
requires concentrations that are 3-fold lower than those needed to inhibit NCX1 and NCX2
453. In contrast to bepridil, KB-R7943 the site of action is located in the extracellular membrane
454.  Previous  studies  have  also  indicated  that  KB-R7943  would  be  a  more  neuroprotective
compound than bepridil 269.
It has been speculated that KB-R7943, with its property to work as an inhibitor for Ca2+
influx  without  effecting  the  normal  Ca2+ efflux 455, could be a better brain homeostasis
stabilizer in ischemic conditions. Study IV tested whether chronic administration of KB-
R7943 (30 mg/kg/day, per os) would prevent secondary neuropathological changes after focal
ischemia in rats. KB-R7943 treated MCAO rats seemed to recover from the post-operative
phase  more slowly than vehicle  treated MCAO rats  based on the  weight  gain.  Behavioral
tests did not reveal any differences between the treatment groups (beam data not shown).
Biochemical  analyses  from  the  thalamic  samples  also  found  no  differences  between  the
treated MCAO groups.
In conclusion, 30 mg/kg/day KB-R7943 treatment starting two days after the initial
ischemic insult did not prevent calcium and A accumulation in the thalamus nor was any
behavioral recovery seen.
6.5 RODENT AND MARMOSET STUDIES – LOST IN TRANSLATION
Although decades of research in the field of stroke have produced tremendous amount of
new knowledge about the pathology of the disease, it has to be stated that we only partially
understand the exact chains of events that begin with the occlusion and end with the delayed
stroke-related pathological changes.
One of the solutions may be the use of non-human primates as a model of stroke 330. The
translational barriers between rodents and humans are poorly defined and the anatomical
and physiological differences between the rodent and human brain have been frequently
cited as potential reasons for pitfalls encountered in extrapolating experimental work to
clinical success 456–458. For example, multiple studies have detected APP/A accumulation in
the thalamus after experimental stroke in rats 92,213,274,  but  this  is  not  seen  in post mortem
samples from patients with cerebrovascular lesions 459.
The study of Tagaya and colleagues showed also that the neuronal response to acute
ischemia is significantly different between rodents and baboons 460. Notably also studies
cross-checking the calcium related NMDAR inhibitor and sodium channel inhibitor effect on
primates and rodents have revealed distinctly different outcome results between the species
461.  In  addition,  several  reports  have described A plaques  in  aged marmosets,  suggesting
that this species may represent a novel animal model of Alzheimer’s disease 462,463.  The use
of common marmosets in the stroke-research could easily combine all the important factors
needed in the preclinical generation of new treatments, i.e., behavioral testing 464, imaging
and histology 465,466.
The  ethical  challenges  inherent  in  primate  research  must  be  carefully  considered  in
embarking on experiments with primates. The argument often made to justify primate stroke
research  tries  to  weight  the  discomfort  experienced  by  the  primate  subjects  against  risk
avoidance  in  subsequent  human  studies  and  potential  benefits  to  humans  through  new
discoveries 467,468.
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In  study  V,  common  marmosets  underwent  3  hour  transient  MCAO.  This  filament
model  is  identical  to  the  model  used  in  rat  studies  I,  II  and  III.  Although  the  number  of
animals was low and areas of infarct varied from animal to animal, one common finding was
observed in all the subcortically infarcted marmosets; a hyperintense MRI signal originating
from the substantia nigra. Alizarin red staining for calcium was also occasionally observed
in the substantia nigra. The inflammation marker, GFAP, showed evidence of an increase in
astroglia reaction in the ipsilateral cortex and thalamus. Most important, there was absolutely
no evidence of calcium or A pathology in the thalamus.
These results suggests that the secondary changes occurring in common marmosets
after a stroke are different to those observed in rodents. Due to the low number of animals,
further studies will be required to verify this conclusion.
6.6 FUTURE PERSPECTIVES
Drug development for acute stroke has proven to be a challenging and difficult road. More
than 1000 neuroprotective compounds have been shown to be effective in experimental
models, but although 114 of these compounds have been tested in stroke patients, it is
disappointing that not one has been clinically effective 38.  Although  there  was  a  broad
definition of what was meant by the term neuroprotection (e.g., intention to prevent stroke-
related neuronal death, restoring blood flow or merely investigating the mechanism of
stroke), the result emphasizes the importance of critical preclinical research and for taking
common directions towards additional phase III preclinical trials. The reasons for failures
have been discussed 293,294,379,457, but may be partly related to the extremely narrow therapeutic
time window. Thus, alternative strategies are urgently needed. One of the most plausible
strategies to overcome the roadblocks in the translation from bench to bedside is
international collaboration between basic scientists and clinicians. Appeals have been made
for more large-scale collaboration and harmonized ways to undertake stroke-research need
to be established 469,470.  As  highlighted  in  the  report  from  Howells  et  al. 471, multicentral
preclinical collaboration with additional computational and in vitro-studies might be a way
to reduce drug development costs by as much as 31 %.
However, less attention has yet been paid to the secondary degeneration in remote
regions after cerebral ischemia. This has been detected in rodents 89,110,117 and imaging data
from stroke patients suggest that there is some degree of shrinkage in the thalamus 80. The
secondary pathology typically develops in delayed manner, thus offering a target for stroke
management  since  it  would  have  a  much  wider  therapeutic  time  window.  There  are
preliminary data, including work done in this thesis, showing that this secondary pathology
is amenable to treatment 132,142,359–364. However, the question remains whether these effects can
be translated into clinical success. The present data from marmoset revealed a lack of A and
calcium pathology, suggesting that results obtained from rodents may not be relevant to
stroke patients. On the other hand, understanding the reason for the difference may provide
a hint of the direction that should be taken by future research.
Another striking feature in the secondary pathology is the similarity to AD pathology.
One immediate question arises: can we use this as a ”fast” model for AD pathology? AD is a
slowly developing neurodegenerative diseases and its pathology is usually seen in old
animals. On the other hand, it is not clear whether removing, dissolving or dissociating A
aggregates, the type of neuropathology often seen towards the end stage of disease, will be
helpful. Often such treatments have secondary effects that are more devastating than the
disease itself. In addition, regrettably few studies have investigated the axonal changes
affecting outcomes in stroke and AD.
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As a  conclusion,  there  is  an obvious  association between stroke and AD.  Changes  in
human vascular pathology have been revealed to increase the risk of AD 45, similarly to the
presence of AD pathology in the human brain has been shown to increase the risk of stroke
45,48. As seen in experimental rodent studies, since calcium and A exhibit two distinct, but
also overlapping pathologies, one could speculate that targeting their crossroads could lead
to a common therapy for both diseases.
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7 Conclusions
The inflammatory process related to the secondary pathology in the thalamus was not
affected by treatment with the anti-inflammatory drug, ibuprofen, or by the non-specific
calcium channel inhibitor, bepridil.
Bepridil  alleviates  the  accumulations  of  calcium  and  A observed  in  the  thalamus  after
cerebral ischemia, and this was to some extent reflected into the behavioral improvement of
the rats. A specific inhibitor of the reverse Na+/Ca2+ exchanger KB-R7943 did not lessen the
pathology or sensorimotor impairment in MCAO rats indicating that excessive Ca2+ influx
into the axoplasm during retrograde degeneration does not play major role in the secondary
pathology occurring after an ischemic lesion.
The  secondary  pathology  in  the  thalamus  after  cerebral  ischemia  was  a  consistent
phenomenon  in  rats  and  mice,  but  it  was  not  detected  in  non-human  primates.  This  is  in
agreement with post mortem studies in patients with cerebrovascular lesions. The reason for
the different pathology remains to be elucidated.
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Stroke and Alzheimer’s disease 
(AD) are the leading causes of 
disability. This thesis aims to study 
the secondary neuropathology 
after experimental stroke, which 
is strikingly similar to that in 
AD. It appears that non-specific 
calcium channel blocker, bepridil, 
prevents calcium and amyloid-beta 
accumulation in the thalamus after 
stroke and this improves functional 
recovery. The thesis also showed that 
secondary neuropathology in rodents 
after stroke was not observed in non-
human primates, which complicates 
the translation of experimental data 
to clinical practice.
